Novel mechanisms and biomarkers in alcohol-induced organ injury. by Dolin, Christine E.
University of Louisville
ThinkIR: The University of Louisville's Institutional Repository
Electronic Theses and Dissertations
5-2019




Follow this and additional works at: https://ir.library.louisville.edu/etd
Part of the Diagnosis Commons, Digestive System Diseases Commons, Hepatology Commons,
Medical Molecular Biology Commons, Medical Toxicology Commons, and the Nephrology
Commons
This Doctoral Dissertation is brought to you for free and open access by ThinkIR: The University of Louisville's Institutional Repository. It has been
accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of ThinkIR: The University of Louisville's Institutional
Repository. This title appears here courtesy of the author, who has retained all other copyrights. For more information, please contact
thinkir@louisville.edu.
Recommended Citation









Christine E. Dolin 
B.S. University of Louisville, 2015 
M.S., University of Louisville, 2017 
 
A Dissertation 
Submitted to the Faculty of the 
School of Medicine of the University of Louisville 
In Partial Fulfillment of the Requirements 
for the Degree of 
 
Doctor of Philosophy in Pharmacology and Toxicology 
 
Department of Pharmacology and Toxicology 








NOVEL MECHANISMS AND BIOMARKERS IN ALCOHOL-INDUCED ORGAN 
INJURY 
By Christine E. Dolin 
B.S., University of Louisville, 2015 
M.S. University of Louisville, 2017 
Dissertation Approved on  
04/12/2019 
By the following Committee: 
 
__________________________________ 




























This dissertation is lovingly dedicated  
to my parents 
Owen and Ann Dolin 
And to my husband 
Neal Taylor 
for their constant love, encouragement and support  





First, I would like to thank my mentors, Dr. Gavin Arteel and Dr. Michael 
Merchant, for their steadfast guidance and support in my research and learning.  
Their encouragement, patience and confidence in my abilities during my first 
scientific investigations and throughout my graduate career has been 
instrumental in the success of my research.  I would also like to thank my 
dissertation committee members, Dr. Michelle Barati, Dr. Juliane Beier, Dr. 
Jonathan Freedman, and Dr. Gary Hoyle, for their guidance and support 
throughout my graduate career.   
I would like to thank Dr. Craig McClain and Dr. Vatsalya Vatsalya for their 
help in providing the alcoholic hepatitis samples and clinical data.  I would also 
like to thank Dr. Shesh Rai and Dr. Sudhir Srivastava for their statistical support.  
I would also like to thank Dr. Wolfgang Zacharias, Sabine Waigel, and Vennila 
Arumugam for their help with RNA-seq, and Dr. Eric Rouchka and Dr. Julia 
Chariker for bioinformatics support.   
Many thanks to my lab mates who have been an instrumental part of my 
graduate experience: Daniel Wilkey, for his proteomics expertise, Susan Isaacs, 
for her expertise in immunoblot, Ming Li, Kim Head, and Deanna Siow for their 
guidance and lab management, Dr. Veronica Massey, Dr. Lauren Poole, Dr. 
Shanice Hudson, Dr. Anna Lang, Dr. Liya Chen, Regina Schnegelberger, Brenna 
v 
 
Kaelin, and Calvin Nguyen-Ho for their peer mentorship and their help with 
various experiments.   
Thank you to everyone in the University of Louisville Department of 
Pharmacology and Toxicology, Alcohol Research Center, and Division of 
Nephrology for your support.  Thanks also to my cohort mates for making 
coursework more enjoyable.   
Finally, I would also like to thank my friends and family for their support 
through my years in graduate school.  Special thanks to Kelsey Durrenberg and 
Adrienne Bushau-Sprinkle for their steadfast friendship.  I would like to thank my 
husband, Neal Taylor, for his endless love, patience and encouragement.  Many 
thanks to my family- Owen, Ann, Matt, and Brad Dolin– for all of their loving 
support throughout my life that made me who I am.  I thank God for each of 
these individuals, and for the opportunity and ability to do the work that is 





NOVEL MECHANISMS AND BIOMARKERS IN ALCOHOL-INDUCED ORGAN 
INJURY 
 
Christine E. Dolin 
April 12, 2019 
 
Background. Ethanol (EtOH) consumption is known to affect multiple organs; 
this is unsurprising, as the concentration of EtOH in the blood at relevant doses 
reaches the millimolar range.  The overarching goal of this dissertation was to 
elucidate mechanisms of alcohol-induced organ injury, specifically the effects of 
alcohol on the hepatic extracellular matrix (ECM) proteome, the alcoholic 
hepatitis (AH) plasma peptidome, and the effects of alcohol on the renal cortex 
proteome and transcriptome.  Methods. Mice were pair-fed ethanol-containing 
liquid diet chronically, and then some mice were administered lipopolysaccharide 
(LPS).  Liver sections from these mice were processed in a series of increasingly 
rigorous extraction buffers to separate proteins by ‘age’ and crosslinking.  
Extracted proteins were identified using liquid chromatography-tandem mass 
spectrometry (LC-MS/MS).  For the AH study, a workflow was developed for the 
peptidomic analysis of plasma from healthy participants or AH patients.  AH 
severity was stratified by MELD score as mild (<12; n=45), moderate (12-19; 
vii 
 
n=23) or severe (>19; n=37).  The peptidome in AH and control plasma was 
analyzed with LC-MS/MS.  For the kidney study, renal cortex proteins were 
extracted in lysis buffer, and RNA was also isolated.  Extracted proteins were 
identified using LC-MS/MS, and RNA sequencing (i.e. transcriptomics) identified 
transcripts.  Results. Chapter III introduced a new proteomic approach for 
characterizing the hepatic matrisome, which demonstrated that the hepatic 
matrisome responds dynamically to both acute (LPS) and chronic (ethanol) 
stresses, long before more dramatic fibrotic changes to the liver.  Chapter IV 
demonstrated that AH causes detectable changes in the plasma ECM 
degradome/peptidome of patients, and that the LC-MS/MS analysis of the 
plasma peptidome is a novel, minimally-invasive method for prognosis 
stratification in patients with AH.  Finally, Chapter V revealed that chronic, 
moderate ethanol consumption affects renal cortical oxidant response pathways 
at the protein and transcript level.  Conclusions.  The work presented in this 
dissertation has, in conclusion, revealed that the hepatic ECM responds 
dynamically to stress, plasma peptides, including ECM peptides, change with AH 
severity, and chronic ethanol consumption affects renal cortical oxidant response 
pathways.   
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A. Background and rationale for this study 
 
1. Alcohol consumption and human health 
Alcoholic beverages were valued in ancient cultures as an antimicrobial 
agent, a source of hydration and nourishment, as well as a “social lubricant” (1). 
Today, alcohol consumption is nearly ubiquitous worldwide.  In the United States 
alone, 86.4% of adults report consuming alcohol at some point in their lives (2).  
Just as alcohol use is common worldwide, so is alcohol abuse.  Chronic, 
compulsive alcohol abuse characterizes clinically recognized alcohol use 
disorder (AUD), which is defined with specific criteria in the Diagnostic and 
Statistical Manual of Mental Disorders (DSM).  AUDs affect approximately 15 
million adults in the United States (2).  Worldwide, an estimated 64 million people 
are dependent on alcohol (3).   
While AUD is, in itself, a brain disorder, the serious health consequences 
of alcohol abuse are much more extensive.  In addition to the brain (4), chronic 
alcohol consumption/abuse directly damages several organs, including the liver 
(5), lung (6), skeletal muscle and heart (7), and pancreas (8).  Alcohol 
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consumption is a risk factor for over 200 health conditions (9).  Alcohol 
consumption accounts for ~6% of all disability-adjusted life years lost in the 
United States, and alcohol-related disease and disability costs the United States 
approximately 250 billion dollars annually (2). There is a great need for 
mechanism-based therapies to treat and/or protect against alcohol-induced 
organ damage, especially given the high rate of relapse of AUDs (10). 
Unfortunately, current therapies for alcohol-induced organ damage are palliative, 
at best, and do not prevent or reverse the progression of organ injuries. The 
overarching goal of this project is to develop such means of detection and 
treatment of alcohol-induced end organ damage.  
 
2. The extracellular matrix: more than a scaffold 
The extracellular matrix (ECM) is a non-cellular three-dimensional scaffold 
within all tissues and organs (11) that is critical for structure and cell signaling.  
Genetic mutations in matrix components can cause a myriad of connective tissue 
pathologies (12-14), if not embryonic lethality (15, 16).  Therefore, the ECM is 
essential to normal tissue homeostasis. 
The most obvious function of the ECM is to physically support cells and 
thereby provide structure to tissue.  The composition of the ECM allows for its 
structural role.  A network of collagens, which provides tensile strength, is a 
major component of the ECM of the basement membranes and interstitial 
matrices in all physiological domains (17).  In all solid organs, fibroblasts secrete 
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fibrous glycoproteins and proteoglycans that adhere to this collagen scaffold in a 
highly cross-linked meshwork (17).   
In addition to its structural role, the ECM can also play a role in cell signaling. 
The heparin and heparan sulfate components of many proteoglycans readily bind 
soluble growth factors, cytokines, and chemokines and can even regulate their 
activation and presentation to cells (18).  Additionally, these signaling molecules 
can become spatially distributed and form gradients by binding to the ECM (18).  
These gradients are important for tissue development and inflammatory cell 
migration (18).   
In addition to binding signaling molecules, ECM proteins can directly engage 
in signaling.  Indeed, ECM proteins are ligands of cell surface receptors, 
including integrins, which bind specific ECM protein domains (e.g., the RGD 
motif) (19).  Through interaction with cell-surface receptors, the ECM can activate 
intracellular signaling (19) 
The ECM is far from static; it is full of activities required to maintain 
homeostasis or (mal)adapt to insult.  Proteases and protease inhibitors are key 
players in maintaining and regulating other ECM components (20).  Proteases 
may deposit (e.g., proteases involved in the complement and coagulation 
cascades) or degrade (e.g. matrix metalloproteinases, MMPs) matrix 
components to facilitate rapid changes in ECM organization.  Alterations in the 
extracellular landscape, including changes in ECM topography, crosslinking, and 
biochemistry, can affect cell migration, adhesion, and activation (21).  Indeed, 
protease-mediated modification of the ECM can have physical and/or 
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biochemical significance.  For example, ECM proteolytic degradation can create 
physical space through which cells can migrate (22).  Alternatively, ECM 
proteolysis can expose or remove binding sites; for example, protease cleavage 
of laminin-5 exposes integrin-binding sites that are necessary for cell adhesion 
(23).  Proteases can also contribute to ECM dynamics by modulating the activity 
of other enzymes (e.g., proteinase precursors (24) and soluble mediators (e.g., 
IL-8, (21)).  Degradation of ECM components, such as the glycosaminoglycan 
components of proteoglycans, can release growth factors (18).  The broad, 
consequential activity of proteases necessitates intricate, and often redundant, 
mechanisms of regulation.  Indeed, proteases are not only regulated at the levels 
of transcription and secretion, but also at the level of activity (25).  Proteases are 
often activated through cleavage by another protease, and can be targeted by 
inhibitors, such as tissue inhibitors of matrix metalloproteinases (TIMPs) (22).  
Therefore, regulation of the ECM is important for the function of tissues and 
organs.   
 
3. The role of the ECM in inflammation and disease 
As previously discussed, tight regulation of the ECM is critical for normal 
tissue homeostasis.  Such regulation also facilitates rapid changes that allow the 
ECM to play a dynamic and responsive role during inflammation and tissue 
repair.  Perturbations in the ECM during either of these physiological states can 
contribute to disease initiation and progression.  Indeed, ECM dysregulation is 
often a hallmark of tissue pathology (16).   
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During hepatic inflammation of any cause, hepatocytes express many 
different chemokines and inflammatory mediators (26).  During hepatocyte injury 
or death, they also release damage-associated molecular patterns (DAMPs), 
which activate resident macrophages (Kupffer cells, KCs).  Additionally, 
pathogen-associated molecular patterns (PAMPs, e.g. LPS) activate pattern 
recognition receptors (PRRs) (27).  DAMPs and PAMPs cause the release of 
cytokines and acute phase proteins (APPs), such as TNFα, IL-1, IL-6.  Hepatic 
stellate cells become activated, and deposit new ECM and alter matrix 
degradation.  Although this response is important for normal 
immune/inflammatory function, dysregulation of this response can cause 
inappropriate inflammation, tissue damage, and hepatic fibrosis.  During 
inflammation and injury, the functions of the ECM include providing structure, 
facilitating adhesion, presenting cytokines to receptors, sequestering and storing 
cytokines, and mechanical signal transduction.   
The ECM plays an important structural role during inflammation and disease.  
Under normal conditions, the ECM defines tissue boundaries (28).  When the 
tissue is injured, the super- and ultra- structure of the ECM is altered.  As a 
result, tissue boundaries are perturbed.  Additionally, injury alters structural 
components of the ECM (e.g. collagens I, IV, V, fibronectin, elastin) and thereby 
affects the normal elasticity provided by the ECM (29).   
Another role of the ECM during inflammation is regulation of the signaling of 
cytokines and other APPs.  The ECM acts as a chemokine reservoir.  
Additionally, ECM binding of cytokines, including IL-2, TNFα, TGFβ, and 
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RANTES ((30-32), has been shown to regulate cell activation, adhesion, and 
migration.  For example, CCL2 is concentrated in the ECM at the site of injury.  
Furthermore, glycosaminoglycan binding of chemokines can protect them from 
proteolytic cleavage.   
The ECM also acts as an adhesive substrate during inflammation.  The ECM 
directs inflammatory cells.  For example, the ECM is critical in the process of 
leukocyte adhesion and transmigration (33).  Initial leukocyte capture and rolling 
is mediated by selectins, arrest is medicated by integrins, and transmigration 
involves adhesion molecules.  The aforementioned chemokine gradients 
mediated by the ECM also play an important role in directing immune cells.   
During inflammation, the ECM also plays an important role in mechanical 
signaling.  During an acute inflammatory response, the ECM plays a pivotal role 
by serving as a structural barrier.  The ECM defines mechanical properties 
permissive and/or instructive to inflammation.  Indeed, studies have shown that 
neutrophil transmigration is greater through vascular areas with lower ECM 
concentration (34).  The interaction between the ECM and cell infiltration is 
bidirectional; as leukocytes integrate structural and biochemical signals from the 
ECM, they in turn release matrix-degrading proteases (35) which alter the 
extracellular composition and allow for easier cell migration.   
ECM dysregulation during chronic inflammation can cause pathological tissue 
remodeling.  Over time, this remodeling can culminate in disease states such as 
hepatic fibrosis (36, 37), pulmonary fibrosis (38-40), atherosclerosis (41, 42), and 
cancer (43, 44).  Dysregulated ECM synthesis and/or degradation can lead to 
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altered matrix accumulation, which is the etiologic basis of these pathologies.  
For example, robustly increased collagen Iα1 secretion by hepatic stellate cells 
(HSCs) (45), increased crosslinking, and a decrease in enzymatic degradation 
(46) all characterize hepatic fibrosis.  These dynamic ECM changes can initiate 
and perpetuate disease through multiple mechanisms, including altered tissue 
biomechanics (i.e. tissue stiffness) (47, 48), increased integrin-mediated cell 
adhesion (49) and activation of immune cells (50).   
 
4. ECM remodeling and the “degradome” 
As discussed previously, the ECM always has some level of dynamicity, even 
under normal conditions, but can undergo more dramatic, rapid changes (i.e. 
remodeling) during inflammation and disease.  Changes in ECM components can 
occur at all different levels, from protein synthesis to crosslinking or activation.  
One important means of regulation of ECM components is through proteases 
(e.g. MMPs).  At different stages of liver injury, hepatic stellate cells express and 
secrete different profiles of proteases and inhibitors (51), as do hepatocytes (52), 
neutrophils (53), and macrophages (54).  These proteases can release cytokines 
from the matrix (55), but can also release a myriad of other peptides that may or 
may not be bioactive.  The roles of protease degradation products (i.e. the 
‘degradome’) in various diseases are becoming increasingly understood.  For 
example, ECM degradation rate, the production rate of matrix degrading 
enzymes (MDE), and the conversion of ECM into soluble ECM have been 
demonstrated to strongly influence tumor growth and morphology (56).  
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Understanding the role of the ECM degradome in disease is facilitated by 
modern mass spectrometry methods that allow widespread characterization of 
the degradome (i.e. peptidomics or ‘degradomics’) (57).  Even if degradation 
products do not play a critical role in disease mechanisms, they may be useful 
surrogate biomarkers.  These peptides are particularly attractive biomarker 
candidates because they are often secreted into bodily fluids (58, 59).  This 
means that they could be detected using minimally invasive procedures (e.g. 
blood draw).   
 
5. Natural history of liver disease 
No matter their etiology, liver diseases share a common natural history that 
has been thoroughly documented.  This natural history is comprised of a 
spectrum of disease states including earlier stages of fatty accumulation and 
inflammation, such as steatosis and steatohepatitis, and later stages of disease 
such as fibrosis and cirrhosis (60, 61).  Simple steatosis is the earliest stage of 
liver disease and is characterized by micro- and macro-vesicular fat 
accumulation.  Steatosis may be reversible with lifestyle modifications or 
progress to steatohepatitis.  Steatohepatitis is characterized by persistent fat 
accumulation, chronic inflammation, and necrosis (27).  Fibrosis and cirrhosis, 
the later stages of liver disease, are characterized by accumulation of fibrillar 
collagens and regenerative nodules, respectively (61, 62).   
Although there is a great need for and large amount of money spent on liver 
disease treatment, therapeutic options are palliative at best.  Currently there is no 
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FDA-approved therapy to halt or reverse liver disease progression.  A better 
understanding of mechanisms of disease progression is needed, and new 
therapeutic targets must be identified if a rational, targeted therapy is to be 
developed.   
 
6. Alcoholic liver disease  
The liver is the primary site of alcohol metabolism and therefore the primary 
target organ of alcohol toxicity.  Indeed, after absorption from the small intestine, 
milli-molar concentrations of ethanol flow through the portal circulation and to the 
liver for degradation.  Ethanol is at least 2-3 times more concentrated in portal 
blood than in systemic circulation (63).  Oxidative metabolism of ethanol in 
hepatocytes by alcohol dehydrogenase (Adh) and cytochrome P450 2E1 
(Cyp2e1) produces toxic intermediate metabolites (e.g., acetaldehyde).  Ethanol 
metabolism also causes a robust increase in the NADH/NAD+ ratio, which 
creates a more reduced cellular environment.  This reduced microenvironment 
blocks the beta-oxidation of fatty acids and increases fatty acid esterification.  
The accumulation of excess fatty acids, which are stored in lipid droplets, 
characterizes steatosis, the earliest stage of alcoholic liver disease (ALD).   
Most individuals who consume moderate amounts of alcohol develop 
steatosis.  Steatosis most often has no health consequences, and may even be 
considered a protective mechanism, as it prevents plasma lipid levels from rising.  
However, chronic alcohol consumption can cause progression to later stages of 
ALD, including alcoholic steatohepatitis (ASH), fibrosis, and cirrhosis.  Only a 
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minority of even the heaviest drinkers will develop the most serious stages of 
ALD.  This suggests a 2-hit hypothesis in which progression to later stages of 
liver disease requires multiple insults, or ‘hits’ (64, 65).  The first ‘hit,’ such as 
hepatic steatosis, sensitizes the liver to a second hit such as oxidative stress (65) 
or inflammatory cytokine signaling (66), both of which are increased by ethanol 
consumption.   
Therefore, alcohol is one of the most commonly recognized causes of liver 
disease.  ALD affects more than 10 million Americans each year with medical 
costs of more than $166 billion annually (67).  There are no targeted therapies for 
ALD, and current therapy focuses on achieving and maintaining abstinence.  
Individuals with severe ALD are at risk of such acute alcoholic hepatitis (AH) or 
cirrhosis (68).  These sequelae of ALD have a poor prognosis and limited 
therapeutic options.  Without a successful liver transplant, patients typically die 
from the effects of decompensation (e.g., hepatorenal syndrome) (69).  
Additionally, cirrhosis increases the overall risk for hepatocellular carcinoma 
(HCC) by roughly 20-fold, even in the case of compensated cirrhosis (70).  Once 
the HCC is symptomatic, it is usually unresectable (71).  This cancer has a 
dismal prognosis, with a median survival of less than 6 months and a five year 
survival of almost nil (71).  While the stages of ALD have been well-
characterized, targeted therapies to prevent or reverse this process in humans 
are still needed.  Therefore, additional research is needed to improve 
understanding of risk factors and mechanisms of disease progression and to 





AH is characterized by severe, acute hepatic inflammation, liver failure, and 
jaundice (72).  It is a sequelae of ALD that typically occurs after many years of 
heavy alcohol consumption, and it has a high mortality rate (30-50% at 3 months, 
(73)).  Cause of death in AH patients is usually due to multiple organ failure 
secondary to liver injury (74). AH patients are also at risk of systemic 
inflammatory response syndrome (SIRS), which is associated with increased 
mortality (75).   
Therapeutic options for AH are limited.  Liver transplantation for AH is 
controversial and is currently not recommended, largely due to organ shortages 
(76).  Current pharmacologic treatment options for AH are limited to 
corticosteroids or pentoxifylline, although the outcomes from the therapies are 
poor.  The benefits of anti-inflammatory pharmaceuticals only outweigh the risks 
(e.g. infection) in patients with more severe AH (72).  For this reason, assessing 
AH severity and predicting patient outcome is important.   
Predicting outcomes of AH patients is challenging.  AH patients typically have 
an AST/ALT greater than 2, but this measure is neither specific nor sensitive 
(77).  Alternatively, several clinical scoring systems have been developed.  The 
Maddrey discriminant function (DF) is based on serum bilirubin and PT/INR (78) 
which are independent predictors of short‐term mortality in AH (79).  The Model 
for End‐Stage Liver Disease (MELD) score similarly utilizes serum bilirubin and 
INR, but also considers creatinine.  MELD has been shown to more accurately 
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predict short‐term mortality in AH compared to DF (80). Other validated scores 
include ABIC, Glasgow Alcoholic Hepatitis Score, the Child-Turcotte-Pugh score; 
these have similar prognostic efficiency as MELD (81-83). These models are 
highly limited in patients with coexisting kidney disease or chronic hemolysis not 
related to the underlying liver disease (78).  Furthermore, scores such as MELD 
are more limited in predicting outcome of patients with more moderate AH (84).   
 
7. Alcohol and the kidney 
It is well established that ethanol is both directly toxic to the liver and can 
sensitize the liver to a second-hit insult.  Although the liver is the primary target 
organ of ethanol toxicity, it is becoming increasingly understood that ethanol has 
some level of toxicity in other organs, such as the brain, gut, lungs, and 
pancreas.  Chronic, heavy ethanol consumption causes kidney damage 
secondary to hepatic cirrhosis, a phenomenon known as hepato-renal syndrome.  
Moderate alcohol consumption, however, is currently not considered a risk factor 
for chronic kidney disease.  Furthermore, population based studies have shown 
moderate alcohol consumption to be inversely associated with kidney injury (85).  
However, the direct renal effects of chronic moderate EtOH consumption and 
sensitization to secondary hits are unclear.  Rodent studies have identified 
several mechanisms of alcohol-induced kidney injury that parallel those observed 
in the liver (86-88).  These investigations have been driven by the hypothesis that 
alcohol affects the kidneys similarly to the liver.  It certainly is not surprising that 
these parallel mechanisms have been confirmed, considering similarities 
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between these two organs, such as the expression of CYP2E1 (86).  However, it 
is certainly possible that ethanol affects the kidneys by mechanisms that do not 
parallel those in the liver.  Therefore, further investigation into the effects of 
ethanol on the kidneys is needed.  Additionally, it is not known whether ethanol 
exposure alters renal response to a second inflammatory ‘hit’, as has been 
observed in the liver.   
 
8. Statement of goals 
It is well established that ethanol is toxic to the liver, and the natural history of 
ALD is well characterized.  However, there are no targeted therapies to halt or 
reverse liver disease.  Development of such therapies requires a better 
understanding of mechanisms of disease progression as well as identification of 
novel drug targets.  Therefore, one goal of this dissertation is to shed new insight 
into mechanisms of progression of ALD.  In contrast to the liver, the effects of 
ethanol on the kidneys are largely unknown.  Therefore, another goal of this 
dissertation is to elucidate mechanisms by which ethanol affects the kidneys.  
Taken together, the goal of this dissertation is to examine new potential 
mechanisms by which ethanol affects the liver and kidneys.   
 
B. Aims and proposals 
 
1. Characterization of alcohol-induced matrisome changes in liver 
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As discussed in earlier sections, the role of the ECM in later stages of liver 
disease (i.e., fibrosis) is well established.  Previous studies from our group and 
others have also demonstrated changes in the ECM in early liver disease, prior 
to fibrogenesis (89-91).  These studies suggest that these transitional ECM 
changes may play an important role in the sensitization of the liver to insult.  
While several matrix proteins have been implicated as players in liver injury and 
inflammation (i.e., fibrin, fibronectin), this is only a small portion of the >1000 
known ECM related proteins (92).  Indeed, other ECM proteins likely also 
contribute to hepatic injury.  Identification of new ECM proteins that ethanol 
exposure alters would help elucidate mechanisms of ALD progression.  There 
are likely changes in the hepatic ECM that have not yet been identified, due to 
the insolubility of matrix proteins that makes them difficult to extract and analyze.  
A limitation of previous studies focused on the role of the ECM in ALD is that they 
generally studied changes in one ECM protein at a time and did not consider 
structural changes that may accompany altered ECM protein turnover.  
Additionally, the study of alterations to the hepatic ECM has primarily been 
hypothesis-driven, which limits the discovery of novel potential players.  This 
study couples a serial extraction method that allows solubilization and 
enrichment of tightly cross-linked proteins with LC-MS/MS analysis.  This 
approach allows analysis of global changes in the hepatic ECM. 
 




AH is characterized by acute liver inflammation and liver failure.  It was 
hypothesized that this inflammation would involve transitional remodeling of the 
hepatic ECM, and that this remodeling would cause the accumulation of ECM 
degradation products (peptides) in the blood.  Therefore, the plasma peptidome 
in AH patients was analyzed.  This builds upon the work in Aim 1 of this 
dissertation, which will demonstrated that the hepatic ECM undergoes significant 
remodeling during inflammatory liver injury (93).  This remodeling involves 
protease cleavage of ECM proteins, which yields ECM peptide fragments (94).  
During remodeling, peptide fragments of the degraded ECM have been shown to 
increase in biologic fluids (e.g. plasma) (58, 59).  Peptidomic analysis of the 
degraded ECM (i.e., ‘degradome) has been identified as a useful 
diagnostic/prognostic tool in other diseases of ECM remodeling, such as chronic 
obstructive pulmonary disease (COPD) (58) and metastatic cancers (59).  
Current methods of predicting AH outcome (i.e. clinical scores, e.g. MELD) are 
limited in their abilities to predict at-risk patients with moderate disease (84).  
Therefore, the purpose of this study was to test the hypothesis that the severe 
inflammatory liver injury caused by AH would yield a unique degradome profile in 
patient plasma.  This was done using a peptidomic workflow analysis of plasma 
from healthy participants or AH patients.  This is expected to reveal unique 
patterns of ECM peptides or ‘features’ across different severity groups of AH 
patients  This analysis lays the groundwork for further studies investigating the 
plasma ECM degradome as potential surrogate or mechanistic biomarkers for 
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AH patient outcome.  The characterization of the AH plasma degradome also 
supports future mechanistic studies on the role of ECM remodeling in AH.   
 
3. Pathways affected by alcohol in the kidney 
The effects of ethanol consumption on the kidneys are poorly understood in 
contrast to the liver.  Some human studies have reported benefits of chronic 
moderate EtOH consumption for preservation of renal function (85, 95).  
However, the small number of rodent studies on the effects of ethanol on the 
kidneys have reported that chronic ethanol consumption upregulates Cyp2e1 
(88), causes neutrophil infiltration (88), and increases acetylation of mitochondrial 
proteins (86) in the kidney.  However, these previous studies have been limited 
by the hypothesis that ethanol affects the kidneys by mechanisms parallel to 
those in the liver.  It was hypothesized that there are additional mechanisms by 
which ethanol affects the kidneys that do not necessarily parallel mechanisms in 
the liver.  Aim 3 of this dissertation tests this hypothesis using a discovery-based 
proteomic and transcriptomic approach to discover novel players and pathways 
affected by ethanol and LPS in the renal cortex.   
 
Overall aim of this dissertation. 
The overall aim of this dissertation is to provide new insight into mechanisms 
of alcohol-induced organ injury.  To this end, a novel method of analyzing the 
hepatic matrisome will be used to determine the effects of chronic, moderate 
ethanol consumption and acute inflammation on the hepatic matrisome in mice 
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(Aim 1).  Next, ECM degradome (peptidome) in AH patient plasma will be 
analyzed (Aim 2), allowing for future investigation into the use of plasma ECM 
peptides as surrogate or mechanistic biomarkers.  Finally, a discovery based 
‘omics approach will be used to elucidate the effects of ethanol consumption on 
the kidneys (Aim 3).  Taken together, this work will shed new mechanistic insight 








A. Animals and exposures 
Animal experiments were carried out by the Arteel laboratory.  Mice were 
housed in a pathogen-free barrier facility accredited by the Association for 
Assessment and Accreditation of Laboratory Animal Care, and procedures were 
approved by the University of Louisville’s Institutional Animal Care and Use 
Committee.  
 
1. Animal sacrifice, tissue collection and storage 
At time of sacrifice, animals were anesthetized with ketamine/xylazine 
(100/15 mg/kg, intraperitoneally (i.p.)).  Blood was collected from the vena cava 
just before sacrifice.  Citrated plasma was stored at -80 ⁰C for further analysis.  
Portions of liver and renal cortex tissue were snap-frozen in liquid nitrogen, fixed 
in 10% neutral buffered formalin for subsequent sectioning and mounting on 
microscope slides, or frozen-fixed in Tissue Tek OCT-Compound (Sakura 
Finetek, Torrance, CA).   
 
2. Carbon tetrachloride model of hepatic fibrosis 
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Male (4-6 weeks old) C57BL6/J mice were purchased from Jackson 
Laboratory (Bar Harbor, ME).  Mice were injected with CCl4 (1 mL/kg i.p.; diluted 
1:4 in olive oil; Sigma-Aldrich, St. Louis, MO) or vehicle  
twice a week for 4 weeks (96). 
 
3. Chronic model of alcohol exposure 
Male (8 weeks old) C57BL6/J mice were purchased from the Jackson 
Laboratory (Bar Harbor, ME).  Mice were given ethanol-containing Lieber-DeCarli 
diet (Dyets, Inc.) ad libitum or pair-fed isocaloric/isovolumetric maltose-dextrin 
control diet (97).  During the exposure period, animals were housed in pairs in 
shoebox cages in a room held at 75 °F.  Diet was provided in vacuum tubes and 
replaced between 4 and 5 pm daily.  Both ethanol-fed animals and their pair-fed 
counterparts received control diet for the first two days of liquid diet feeding to 
allow acclimation to the liquid diet feeders.  After 2 days of acclimation, ethanol 
concentrations increased incrementally over the course of three weeks before 
reaching the highest ethanol concentration, 6% (vol/vol) for the final three weeks 
of exposure.  Ethanol concentrations in the ethanol-containing diets were as 
follows: 0% for two days of acclimation, 1% for two days, 2% for two days, 4% for 
one week, 5% for one week, and 6% for three weeks.  Ethanol-containing diet 
was provided ad libitum for the entire course of the study.  Because of the 
relatively high caloric content of ethanol, pair-fed control animals received an iso-
caloric control diet; the calories in the iso-caloric diet were matched by adding a 
calorie-equivalent of maltose-dextrin.  To account for the reduced food 
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consumption of ethanol-fed mice, pair-fed mice were given the volume of diet 
consumed by their ethanol-fed counterparts the night before. At the conclusion of 
the feeding period, the two diet groups were further separated into additional 
groups that received either LPS (Escherichia coli; 10 mg/kg i.p. Sigma, St. Louis, 
MO) or vehicle (saline). Animals were euthanized 4 or 24 h after LPS (or vehicle) 
injection (97).  6 control mice, 5 ethanol mice, 6 24-h LPS mice, and 4 
ethanol+24h LPS mice were used for the hepatic matrisome analysis.  3 control 
mice, 3 ethanol mice, 3 4h LPS mice, and 3 ethanol+4h LPS mice were used for 
the renal cortex proteomic and transcriptomic analyses.  The same mice were 
used for the renal cortex proteomics and transcriptomics, except for 1 4h LPS 
mouse and 1 ethanol+4h LPS mouse that were different.   
 
4. Chronic+binge model of alcohol exposure 
Male (10 weeks old) C57BL6/J mice were purchased from the Jackson 
Laboratory (Bar Harbor, ME).  Mice were exposed to ethanol as described by 
Bertola et al. (98).  During the exposure period, animals were housed in pairs in 
shoebox cages in a room held at 75 °F.  Diet was provided in vacuum tubes and 
replaced between 4:00 and 5:00 PM daily.  Animals were acclimatized to control 
(0% EtOH) Lieber-DeCarli liquid diet (Dyets, Inc., Bethlehem, PA) for 5 days.  
Mice were then split into two groups fed ethanol-containing (5% v/v) or iso-caloric 
control liquid diet for 10 days.  To account for the reduced food consumption of 
ethanol-fed mice, pair-fed mice were given the volume of diet consumed by their 
ethanol-fed counterparts the night before.  On day 11, mice received ethanol (5 
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g/kg) or iso-caloric maltose dextran binge via oral gavage.  Mice were sacrificed 
9 hours post-gavage.  Tissues were collected as described in section A1.   
 
B. Proteomics 
1. 3-step ECM extraction 
Sequential extraction of the hepatic ECM was performed as described by 
de Castro Bras et al. for heart tissue (99), with minor modifications for liver.  
Sample preparation and wash. Snap frozen liver tissue  (75-100 mg) was 
immediately added to ice-cold phosphate-buffered saline (pH 7.4) wash buffer 
containing commercially available protease and phosphatase inhibitors (Sigma 
Aldrich) and 25 mM EDTA to inhibit proteinase and metalloproteinase activity, 
respectively.  While immersed in wash buffer, liver tissue was diced into small 
fragments using a scalpel.  The diced sample was washed 5 times to remove 
contaminants.  Between washes, samples were pelleted by centrifugation 
(12,000×g, 5 min), and wash buffer was decanted.   
NaCl extraction.  Diced samples were incubated in 10 volumes of 0.5 M 
NaCl buffer, containing 10 mM Tris HCl (pH 7.5), proteinase/phosphatase 
inhibitors, and 25 mM EDTA.  The samples were mildly mixed on a plate shaker 
(800 rpm) overnight at room temperature.  The following day, the remaining 
tissue pieces were pelleted by centrifugation (10,000×g for 10 min).  The pellet 
was used for the SDS extraction (see below).  The supernatant was collected 
and desalted using ZebaSpin columns (Pierce) according to manufacturer’s 
instructions.  To precipitate proteins, desalted supernatant was incubated with 5x 
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supernatant volume of 100% acetone overnight at -20 °C, centrifuged (16,000×g, 
45 min), and dried in a rotary evaporator.  Proteins were resuspended in 
deglycosylation buffer.  SDS extraction.  The pellet from the NaCl extraction was 
subsequently incubated in 10 volumes (based on original weight) of 1% SDS 
solution, containing proteinase/phosphatase inhibitors and 25 mM EDTA.  The 
samples were mildly mixed on a plate shaker (800 rpm) overnight at room 
temperature. The following day, the remaining tissue pieces were pelleted by 
centrifugation at 10,000×g for 10 min.  The pellet was used for the GnHCl 
extraction (see below).  The supernatant was collected and desalted using 
ZebaSpin columns (Pierce) according to manufacturer’s instructions.  To 
precipitate proteins, desalted supernatant was incubated with 5× supernatant 
volume of 100% acetone overnight at -20 °C, centrifuged (16,000×g, 45 min), 
and dried in a rotary evaporator.  Proteins were resuspended in deglycosylation 
buffer.  Guanidine HCl extraction. The pellet from the SDS extraction was 
incubated with 5 volumes (based on original weight) of a denaturing guanidine 
buffer containing 4 M guanidine HCl (pH 5.8), 50 mM sodium acetate, 25 mM 
EDTA, and proteinase/phosphatase inhibitors.  The samples were vigorously 
mixed on a plate shaker at 1200 rpm for 48 hours at room temperature; vigorous 
shaking is necessary at this step to aid in the mechanical disruption of ECM 
components.  The remaining insoluble components were pelleted by 
centrifugation at 10,000×g for 10 minutes.  This insoluble pellet was retained and 
solubilized as described below.  To precipitate proteins, the supernatant was 
mixed with 6× supernatant volume of 100% ice cold ethanol overnight at 20 °C, 
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centrifuged (16,000×g, 45 min), and washed with 90% ethanol.  Pellets were 
dried in a rotary evaporator and resuspended in deglycosylation buffer.  
Deglycosylation and solubilization.  The supernatants from each extraction were 
dried in a rotary evaporator and resuspended in deglycosylation buffer containing 
150 mM NaCl, 50 mM sodium acetate, 10 mM EDTA, and 
proteinase/phosphatase inhibitors.  Resuspended samples were desalted using 
ZebaSpin columns (Pierce) according to manufacturer’s instructions.  The 
desalted extracts were then mixed with 5 volumes of 100% acetone and stored at 
-20°C overnight to precipitate proteins.  The precipitated proteins were pelleted 
by centrifugation at 16,000×g for 45 minutes.  Acetone was evaporated by 
vacuum drying in a rotary evaporator for 1 hour.  Dried protein pellets were 
resuspended in 500 µL deglycosylation buffer containing 150 mM NaCl, 50 mM 
sodium acetate, pH 6.8, 10 mM EDTA, and proteinase/phosphatase inhibitors 
that contained chondroitinase ABC (P. vulgaris; 0.025 U/sample), endo-beta-
galactosidase (B. fragilis; 0.01 U/sample) and heparitinase II (F. heparinum; 
0.025 U/sample).  Samples were incubated overnight at 37°C.  20 uL DMSO was 
added to the insoluble fraction (pellet from guanidine HCl extraction) to aide in 
solubilization.  Protein concentrations were estimated by absorbance at 280 nm 
using bovine serum albumin (BSA) in deglycosylation buffer for reference 
standards. 
 
2. Total protein extraction 
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This extraction was carried out in the Merchant laboratory.  Proteins were 
extracted from snap frozen renal cortex tissue using lysis buffer (1:1 w/v) 
containing 10% glycerol, 50 mM HEPES, 100 mM KCl, 2 mM EDTA, 0.1% 
Nonidet p-40 (NP-40), 2 mM DTT, 10 mM NaF, 0.25 mM NaVO3, and 1x Halt 
Protease and Phosphatase Inhibitor Cocktail (ThermoFisher).  Samples were 
placed in a sonication bath for 5 minutes, incubated on ice for 1 hour, and 
centrifuged at 12,000×g for 30 minutes.  Extract was removed from insoluble 
matter.  Protein concentrations were assayed using standard Bradford assay with 
BSA for reference standards. 
 
3. Sample cleanup and preparation for liquid chromatography and 
mass spectrometry 
Liver ECM extracts in deglycosylation buffer were pooled by experimental 
group and subsequently analyzed by the University of Louisville Proteomics 
Biomarkers Discovery Core (PBDC).  At the PBDC, samples in deglycosylation 
buffer were thawed to room temperature and clarified by centrifugation at 
5,000xg for 5 min at 4°C.  50 µL (25 µg) of each sample were reduced by adding 
5.55 µL of 1 M DTT and incubating at 60°C for 30 min.  144.45 µL of 8 M urea in 
0.1 M Tris-HCl, pH 8.5, was added to each sample.  Each reduced and diluted 
sample was digested with a modified Filter-Aided Sample Preparation (FASP) 
method developed by Jacek R. Wisniewski, et al. (100).  Recovered material was 
dried in a rotary evaporator and redissolved in 200 μL of 2% (v/v) acetonitrile 
(ACN)/0.4% formic acid (FA).  The samples were then trap-cleaned with a C18 
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PROTOTM 300Å Ultra MicroSpin Column (The Nest Group, Southborough, MA).  
The sample eluates were stored at -80°C for 30 min, dried in a rotary evaporator, 
and stored at -80°C.  Before liquid chromatography, dried samples were warmed 
to room temperature and dissolved in 2% (v/v) ACN/0.1% FA to a final 
concentration of 0.25 μg/μL.  16 μL (4 μg) of sample was injected into the 
Orbitrap Elite. 
Renal cortical proteins (100µg) were digested using a FASP protocol (100) 
to remove NP-40 detergent used for sample preparation.  Proteomic analysis of 
tissue lysates was conducted as previously described (101) with the following 
modifications.  Proteins were digested with Lys-c (Promega #V167A) and trypsin 
(Promega #V5111), each at a 1:100 w/w enzyme:protein ratio.  Peptides were 
desalted using HLB extraction (Waters Oasis HLB 1cc, WAT094225) (102).  50 
µg peptide were dried and resuspended in 100µL 100mM triethylammonium 
bicarbonate (TEABC).  Peptide concentrations were measured using an A205 
nm assay with an external peptide standard curve.   
 
4. TMT labeling 
Tandem mass tag (TMT) 10-plex labeling (Thermo 90111) of renal cortical 
digests was carried out according to manufacturer’s instructions.  50 µg peptide 
in 100 µL 100 mM TEABC were added to each label tube.  Labeled samples 
were admixed, dried, and resuspended in 800 µL 0.1% v/v FA.  Peptide 
concentrations were measured using an A205 nm assay with an external peptide 
standard curve.  200 µg peptide were fractionated by strong cation exchange 
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using 30-300 µg capacity SCX MacroSpin Columns (SMM HIL-SCX.25, Nest 
Group, Inc. Southborough, MA, USA) according to manufacturer’s instructions. 
Sample cleanup was performed using C18 PROTO, 300 Å Ultra Microspin 
Columns (Nest Group, Inc., Southborough, MA, USA).   
 
5. Liquid chromatography and tandem mass spectrometry 
At the PBDC, liver digest samples were separated on a Dionex Acclaim 
PepMap 100 75 μm x 2 cm nanoViper (C18, 3 µm, 100 Å) trap and Dionex 
Acclaim PepMap RSLC 50 μM x 15 cm nanoViper (C18, 2 µm, 100 Å) separating 
columns.  An EASY n-LC (Thermo, Waltham, MA) UHPLC system was used with 
buffer A = 2% (v/v) ACN/ 0.1% (v/v) FA and buffer B = 80% (v/v) ACN / 0.1% 
(v/v) FA as mobile phases.  Following injection of the sample onto the trap, 
separation was accomplished with a 140 min linear gradient from 0% B to 50% 
B, followed by a 30 min linear gradient from 50% B to 95% B, and lastly a 10 min 
wash with 95% B.  A 40 mm stainless steel emitter (Thermo, Waltham, MA; P/N 
ES542) was coupled to the outlet of the separating column.  A Nanospray Flex 
source (Thermo, Waltham, MA) was used to position the end of the emitter near 
the ion transfer capillary of the mass spectrometer.  The ion transfer capillary 
temperature of the mass spectrometer was set at 225°C, and the spray voltage 
was set at 1.6 kV. 
An Orbitrap Elite – ETD mass spectrometer (Thermo) was used to collect 
data from the LC eluate.  An Nth Order Double Play with ETD Decision Tree 
method was created in Xcalibur v2.2.  Scan event one of the method obtained an 
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FTMS MS1 scan for the range 300-2000 m/z.  Scan event two obtained ITMS 
MS2 scans on up to ten peaks that had a minimum signal threshold of 10,000 
counts from scan event one.  A decision tree was used to determine whether 
collision induced dissociation (CID) or electron transfer dissociation (ETD) 
activation was used.  An ETD scan was triggered if any of the following held:  an 
ion had charge state 3 and m/z less than 650, an ion had charge state 4 and m/z 
less than 900, an ion had charge state 5 and m/z less than 950, or an ion had 
charge state greater than 5; a CID scan was triggered in all other cases.  The 
lock mass option was enabled (0% lock mass abundance) using the 371.101236 
m/z polysiloxane peak as an internal calibrant.   
TMT-labeled renal cortex tryptic digest SCX fractions underwent 1D-LC-
MS/MS analysis using a Proxeon EASY-nLC 1000 UHPLC and nanoelectrospray 
ionization into an Orbitrap Elite mass spectrometer (Thermo) using a transfer 
capillary temperature set of 225°C and the spray voltage of 1.6kV.  An Nth Order 
Double Play method was used with scan event one.  An FTMS MS1 scan 
(normal mass range; 60,000 resolution; full scan type) for the 400-2000 m/z 
range was used, with charge state screening and monoisotopic precursor 
selection enabled.  Charge state rejection was enabled for unassigned charge 
states and +1 charge states.  The lock mass option was enabled (0% lock mass 
abundance) using the 445.120028 m/z polysiloxane peak as an internal calibrant.  
Scan event two obtained HCD FTMS MS2 scans (normal mass range; 60,000 
resolution; centroid data type) on up to twelve peaks that had a minimum signal 
threshold of 5,000 counts from scan event one.  Dynamic exclusion was enabled 
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with a repeat count of one, a repeat duration of 60 seconds, an exclusion list size 
of 500, an exclusion duration of 60 seconds, and an exclusion mass width of 
±0.001% relative to reference mass (93).   
 
6. Informatics 
The hepatic ECM mass spectrometry data were analyzed at the University of 
Louisville PBDC using Proteome Discoverer v1.4.0.288.  The database used in 
Mascot v2.4 and SequestHT searches was the 6/2/2015 version of the UniprotKB 
Mus musculus reference proteome canonical and isoform sequences.  +57 on C 
(Carbamidomethylation) was selected as a fixed modification, and +1 on N (Asn-
>Asp) and +16 on MP (Oxidation) were selected as variable modifications.  A 
maximum of two missed cleavages were allowed.  A Target Decoy PSM 
Validator node was included in the Proteome Discoverer workflow in order to 
estimate the false discovery rate (FDR).   
The Proteome Discoverer analysis workflow allows for extraction of MS2 
scan data from the Xcalibur RAW file, separate searches of CID and ETD MS2 
scans in Mascot and Sequest, and collection of the results into a single file (.msf 
extension). The resulting .msf files from Proteome Discoverer were loaded into 
Scaffold Q+S v4.3.2.  Scaffold was used to calculate the FDR using the Peptide 
and Protein Prophet algorithms.  Protein identification probability of the 
sequences was set to >95% on the software.  The results were annotated with 
mouse GO information from the Gene Ontology Annotations Database.   
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Renal cortex mass spectrometry data were analyzed at the University of 
Louisville PBDC using Proteome Discoverer v1.4.0.288 and Scaffold Q+S v4.3.2 
with the 6/2/2014 version of the UniprotKB Mus musculus reference proteome 
canonical and isoform sequences.  A Target Decoy PSM Validator node was 
used to control the FDR and a Reporter Ions Quantifier node was included for 
quantification of the TMT reporter ions considering TMT purity correction factors 
obtained from the manufacturer.  Intensity based normalization of reporter ions 
was achieved using the mean calculation type, modeled on unique peptides, and 
using an average protein reference.  Scaffold was used to calculate the FDR 
using the Peptide and Protein Prophet algorithms.   
 
C. Immunoblots 
1. Dot blot 
Liver samples from the chronic EtOH model were homogenized in 
radioimmunoprecipitation assay (RIPA) buffer containing protease and 
phosphatase inhibitor cocktails (Sigma; St. Louis, MO).  10 μg protein in 100 μl 
RIPA buffer were loaded onto nitrocellulose membranes (GE Healthcare) using a 
vacuum-assisted microfiltration system (Bio-Dot; Bio-Rad, Hercules, CA).  The 
membrane was blocked for one hour with 5% non-fat milk in TBST.  Primary 
antibodies against collagen type I α1 (Meridian T40777R) and GAPDH (Santa 
Cruz SC-25778) were used.  Densitometric analysis was performed using UN-




2. Western blot 
Renal cortex immunoblot was carried out as described previously (103) using 
a primary antibody against Cat (Cell Signaling D5N7V).  Densitometry of 




1. RNA isolation 
Snap frozen renal cortex sections were stored at -80° C and then incubated in 
RNAlater-ICE (Life Technologies, Carlsbad, CA) at -20° C for 72 hours prior to 
RNA extraction.  RNA was isolated using the mirVana kit (Life Technologies, 
Carlsbad, CA) according to manufacturer’s instructions for total RNA isolation.  
RNA quality was evaluated by Nanodrop ND-1000 (Thermo Fisher Scientific, 
Grand Island, NY) and Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA) 
analysis.  Ribosomal depletion was carried out at the University of Louisville 
Center for Genetics and Molecular Medicine (CGeMM) prior to RNA seq 
analysis.   
 
2. RNA sequencing 
RNA libraries were prepared using the TruSe Stranded Total RNA LT 
sample preparation Kit- Set A with Ribo-Zero Gold.  Sequencing was performed 
on the University of Louisville CGeMM’s Illumina NextSeq 500/550 75 cycle High 




3. RNASeq data analysis 
RNA Seq data were analyzed at the University of Louisville CGeMM using 
the Tuxedo suite data analysis pipeline.  Differentially expressed transcripts were 
identified by filtering by analysis of variance (ANOVA) p-value cutoff (p<0.05), a 
more stringent Benjamini-Hochberg (BH) q-value cutoff (q<0.01) and FC cutoffs 
of 1.2 (to explore pathways analysis) and 2 (to address larger changes in RNA 
expression). 
 
E. Histology and Immunohistochemistry 
1. Histology 
In the Arteel laboratory, paraffin-embedded, formalin fixed liver sections from 
the CCl4 study were stained with Sirius Red/Fast Green to visualize fibrosis (96).   
Paraffin-embedded, formalin fixed renal cortex sections from the chronic 
EtOH study were periodic acid-Schiff (PAS) stained (103) in collaboration with 
Dr. Michelle Barati.  Blinded histology was reviewed by a fellowship-trained, 
board certified pathologist.  It was determined that there were no differences 
between groups, and so staining was not quantified.   
 
2. Immunohistochemistry 
In collaboration with Dr. Michelle Barati, immunohistochemistry (IHC) was 
carried out on renal cortex sections using a primary antibody against 
myeloperoxidase (Mpo, Abcam ab9535) and catalase (Cat, Cell Signaling 
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D5N7V) (103).  Mpo staining was quantified as average number of Mpo positive 
cells per visual field (40x) with an average number of 33 ± 4 visual fields per 
kidney section.  An n of 3 samples in each experimental group were analyzed.  
Differences between groups were determined by 2-way ANOVA and post-hoc t-
tests.   
 
F. Clinical chemistry 
1. Blood urea nitrogen analysis 
Blood urea nitrogen (BUN) in mouse plasma from the chronic and 
chronic+binge EtOH studies was measured using the Urea Assay Kit (Abnova 
KA1652) according to manufacturer’s instructions.   
 
G. Clinical study 
1. Study participants 
Plasma samples and clinical data from the following study were provided 
through collaboration with Dr. Craig McClain and Dr. Vatsalya Vatsalya.  This 
study was approved by the Institutional Review Boards at all the participating 
centers.  This study was a part of a large national multisite clinical trial indexed at 
clinicaltrials.gov: NCT01922895 and NCT01809132. All moderate and severe AH 
patients were enrolled at the University of Louisville, the University of 
Massachusetts Medical School, the University of Texas-Southwestern and the 
Cleveland Clinic.  All AUD (“mild”) patients were enrolled at NIAAA, NIH.  All 
healthy volunteers were recruited at the Louisville site.  All AH patients were 
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diagnosed using clinical and laboratory criteria described by the NIAAA 
consortium on AH (104).  Individuals with or without liver injury met the criteria for 
AUD based on DSM 4 XR or DSM 5 manual.  All healthy participants were free of 
any clinically diagnosed disease (liver or organ systems) that might contribute to 
altered laboratory values in comparison analyses.  All patient specimens and 
data were analyzed at the University of Louisville. 
 
2. Inclusion criteria 
Eligible participants were 21 years old or older.  The following individuals 
were ineligible for participation 1) those unwilling or unable to provide informed 
consent; and/or 2) those who had significant comorbid conditions (heart, kidney, 
lung, neurological or psychiatric illnesses, sepsis) and/or active drug abuse; 
and/or 3) pregnant/lactating women; and/or 4) prisoners or other vulnerable 
persons.   
 
3. Study paradigm 
112 adult male and female individuals participated in this NIH-funded study.  
This investigation was a single time point assessment of patients between the 
study cohorts.  The cohorts included healthy participants (n=7), patients with 
AUDs (“mild” , MELD<12; n=45), patients with “moderate” AH (MELD=12-19; 
n=23), patients with “severe” AH (>19; n=37).  The mild/AUD group was both 
analyzed as whole and also as sub-groups without liver injury (“mild-A”, serum 
alanine aminotransferase (ALT)<40, n=14) and with liver injury (“mild-B”, 
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ALT≥40, n=31).  Informed consent was obtained from all study participants 
before collection of data and bodily samples.  Clinical data, relevant medical 
history, measures of severity of ALD, and drinking history [using the Alcohol Use 
Disorders Identification Test (AUDIT) (105) (only in moderate and severe AH 
patients) and lifetime drinking history (LTDH) in all AH and AUD patients (106) 
were collected.  The study was designed to analyze plasma peptides for 
comparison between healthy volunteers, AUD patients (with or without liver 
injury), patients with moderate AH, and patients with severe AH for potential 
associations between parameters.  All data collected from the enrolled study 
participants were de-identified, coded, and analyzed.   
 
4. Collection of clinical data 
Clinical data include participant demographics [age, sex, body mass index 
(BMI)], drinking history (AUDIT and LTDH), medical assessments at admission 
(after obtaining consent, specific for the study to exclude any condition that might 
affect liver tests), and medical history.  Confirmatory tests for AH (laboratory and 
imaging), and markers of liver disease severity [Child-Turcotte-Pugh (CTP), 
MELD, Maddrey DF] were also obtained. Laboratory tests included a 
comprehensive metabolic profile with indices of liver injury [including serum ALT), 
aspartate aminotransferase (AST), total bilirubin (Tbili)] and coagulation.   
 
5. Plasma collection 
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Blood samples were collected from each study participant following consent.  
Blood was collected in lavender- top Vacutainer tubes containing K3 EDTA.  
Blood was separated by centrifugation, and plasma was apportioned into 1 mL 
aliquots and stored at -80 °C until use.  Freeze-thaw cycles were avoided to 
maintain the integrity of the plasma.   
 
H. Peptidomics 
1. Peptidomic workflow optimization 
During workflow optimization, peptides were purified by ACN precipitation.  
100 µL plasma were acidified with 100 µL 10% v/v acetic acid.  To precipitate 
proteins and impurities, 600 µL 99.9% v/v ACN / 0.1% v/v trifluoroacetic acid was 
added to each sample, on ice.  Samples were vortexed for 30 seconds, and 
precipitate was pelleted by centrifugation at 15,000 × g for 15 minutes at 4 °C.  
Pellets were discarded.  Supernatants were collected and centrifuged again as 
before.  Again, supernatants were collected, and pellets were discarded.   
Samples underwent cleanup and LC-MS/MS analysis as described in 
sections 3 and 4.  The LC-MS/MS analysis determined that the purity of the 
peptide samples was unsatisfactory for the relative quantification of peptide 
abundance.  For this reason, the ACN precipitation method was abandoned.  The 
trichloroacetic acid (TCA) precipitation approach developed by Parker et al, 
described below, was adopted (107).  Parker et al. demonstrated that TCA 
precipitation yields more peptides compared to ACN precipitation, acetone 




2. Plasma peptide purification 
To avoid systematic bias, the plasma samples were handled as four sample 
flights (flight 1-4), each composed of balanced proportions of all groups with the 
sample order interwoven into a randomized fashion.  Total plasma peptides were 
purified by TCA precipitation based on Parker et al. (107).  100 µL PBS with K3 
EDTA was added to 100 µL plasma.  Samples were mixed and incubated at RT 
for 5 minutes.  Samples were placed on ice, and 200 µL 20% w/v TCA (prechilled 
to 4 °C) were mixed into each sample.  Samples were allowed to incubate for 1 
hour on ice.  Precipitate was pelleted by centrifugation at 16,000 × g for 10 
minutes at 4 °C; pellets were discarded.  Supernatant collection, centrifugation 
and discarding of pellets was repeated twice to ensure efficient removal of high 
molecular weight proteins.   
 
3. Peptide sample cleanup and preparation for liquid chromatography 
and mass spectrometry 
275 µL of each sample was desalted and concentrated using solid phase 
extraction (Waters Oasis HLB µElution 30 µm plate, part no. 186001828BA) as 
previously described by Keshishian, et al. (102).  Solid phase extraction eluates 
were dried in a rotary evaporator, and dried peptides were resuspended in 25 µL 
2% v/v ACN/ 0.1% v/v FA.  Peptide concentrations were measured by 




4. Liquid chromatography and tandem mass spectrometry 
A high mass accuracy approach was used for relative quantification of plasma 
peptides isolated from AH patients, AUD patients with and without liver injury, 
and healthy volunteers plasma samples using a label-free approach.  Peptides 
were prepared to a concentration of 0.1 µg/µL in 2% v/v ACN/ 0.1% v/v FA.  A 
commercial mixture of 11 synthetic peptides (iRT1-11, Biognosis USA, Beverly, 
MA) eluting across the chromatographic retention time spectrum were spiked into 
each sample following peptidome resuspension.  Peptides were separated by 
reverse phase chromatography on a Proxeon EASY-nLC 1000 UHPLC system.  
2 µL (0.2 µg) of each peptide sample was injected in random order.  The trap 
column used was a 75µm i.d. x 2cm Acclaim PepMapTM 100 nanoViper 
cartridge packed with C18, 3µm, 100Å material(Thermo); the separating column 
used was a 75µm i.d. x 50cm Acclaim PepMap RSLC nanoViper column packed 
with C18, 2µm, 100Å material (Thermo).  The separation was performed with a 
gradient of solvent A = 2% v/v ACN / 0.1% v/v FA and solvent B = 80% v/v ACN / 
0.1% v/v FA.  After loading the sample onto the trap for 6min at 2µL/min in 
solvent A, the sample was eluted and separated at 250nL/min with a gradient 
from 0% to 55% solvent B over 165min.  Following the gradient, the columns 
were washed at 300nL/min for 10min with 95% solvent B and then returned to 
initial conditions. 
Liquid chromatography eluate was analyzed with an Orbitrap Elite mass 
spectrometer with nanoelectrospray ionization.  An Nth Order Double Play was 
created in Xcalibur v2.2.  Scan event one of the method obtained an FTMS MS1 
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scan (normal mass range; 240,000 resolution, full scan type, positive polarity, 
profile data type) for the range 300-2000m/z.  Scan event two obtained ITMS 
MS2 scans (normal mass range, rapid scan rate, centroid data type) on up to 
twenty peaks that had a minimum signal threshold of 5,000 counts from scan 
event one.  The lock mass option was enabled (0% lock mass abundance) using 
the 371.101236m/z polysiloxane peak as an internal calibrant.  
 
I. Informatics 
1. Liver ECM proteomic data analysis 
Hepatic protein enrichment was quantified using total ion current (TIC).  
Within Scaffold, proteins were filtered for extracellular GO annotation.  The NaCl, 
SDS, GnHCl, and pellet fractions contained 89, 63, 84, and 46 extracellular 
proteins, respectively.  Additional analysis was only performed on these proteins 
that were classified as extracellular by GO annotation.  The extracellular proteins 
were further categorized into four classes based on their role in the extracellular 
space as determined by a comprehensive literature search.  These four ECM 
groups include class 1) glycoproteins and proteoglycans, class 2) other ECM-
associated proteins, class 3) proteases and protease inhibitors, and class 4) 
collagens.  If no record could be found supporting the hypothesis that a protein 
was associated with the ECM, the protein was placed into (5), other proteins.   
 
2. Renal cortex proteomic data analysis 
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Renal cortex data were filtered by BH corrected ANOVA p-value <0.05 and 
fold change (FC) ≥ 1.2.  Ingenuity Pathways Analysis (IPA) was used to identify 
pathways changed by EtOH, LPS, and/or the combination.  The PANTHER web 
application was used to identify statistically overrepresented GO cellular 
compartments in groups of proteins that were significantly regulated by EtOH, 
LPS, and EtOH + LPS compared to control.  The statistical overrepresentation 
test was carried out for (A) GO cellular component complete, (B) within each 
cellular compartment, and (C) for GO biological process complete and with 
Bonferroni correction using default settings.   
 
3. Multivariate analysis of renal cortex proteomic and transcriptomic 
data sets 
Hierarchical clustering of the top-20 GO biological process terms for the 
proteomic and the transcriptomic data sets were conducted using the 
Heatmapper web application (www.heatmapper.ca).  Data were clustered using 
an average linkage method and a Spearman Rank Correlation distance 
measurement method. 
 
4. AH plasma peptidome data analysis 
Peptide spectra collected in a data dependent fashion were interpreted using 
a de novo spectrum assignment approach that enabled shotgun analysis of 
peptide post-translational modification.  The AUC for high resolution extracted ion 
chromatograms were used as a label-free relative quantification of the peptide 
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abundances.  Quantitative and qualitative feature data were extracted and 
analyzed using PEAKS Studio (v8.5).  Data were normalized to TIC.  The 
following data analysis was done in collaboration with Dr. Shesh Rai and Dr. 
Sudhir Srivastava.  There were 1730 peptides initially.  In each group, a peptide 
was discarded if all observations were missing.  Therefore, peptides having at 
least one observation across all samples in each group were retained for further 
analysis.  After this filtering, 1273 peptides remained.  Data were normalized by 
taking log base 2 of raw data followed by quantile normalization using 
“normalize.quantiles” function (108) available in R package “preprocessors”.  
Missing values were imputed  using the “SVD” (109) method under the 
assumption of MAR.  The R package “imputeLCMD” was used for imputing the 
missing values. We used the imputed data for further analysis (see section J2). 
 
J. Statistics 
1. Statistical analysis of liver ECM proteomic data 
Heat maps were compiled in the Arteel laboratory by Dr. Shanice Hudson in 
the open-source statistical programming language R (R Development Core 
Team. R: A language and environment for statistical computing.Vienna, Austria: 
R Foundation for Statistical Computing, 2008.).  ECM proteome output as Log2 
FC of control was analyzed with the heatmap.2 function of the gplots package, 
using the methods described by Key et al. (110)  Pearson’s correlation coefficient 
was used to measure distance, and the Ward method (ward.D) was the 
agglomeration method for row and column clustering.  In addition, protein 
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distribution patterns across the four treatment groups were clustered using 
hierarchical clustering (function hclust within R package cluster) (Cluster analysis 
basics and extensions: R package version [computer program]. Version 1.15.3 
2014).  Patterns were clustered separately for each fraction, and the optimal 
number of clusters was determined using a combination of statistical measures 
(R package clValid) (Brock G, Pihur V, Datta S, Datta S. clValid: An R package 
for cluster validation. Journal of Statistical Software 2008;25:1-22.) and biological 
interpretability.  Since interest was in the pattern of abundance across the 
treatment groups, abundance values for each protein were standardized to mean 
zero and standard deviation one for each protein prior to clustering.   
 
2. Statistical analysis of alcoholic hepatitis plasma peptidomic data 
Statistical analyses of the peptidomic data were carried out in collaboration 
with Dr. Shesh Rai and Dr. Sudhir Srivastava.  A non-discriminant data reduction 
method termed principal components analysis (PCA) was used to evaluate the 
data at the patient level and determine the ability of the data to ‘self-sort’ into 
discrete groups.  To evaluate the data more discretely at the peptide level, a 
multivariate analysis approach using hierarchical clustering and heat-map 
annotation was used incorporating linear mixed modeling of the data to control 
for fixed and random variables.  Lastly, univariate (pair-wise t-tests with 
Benjamini-Hochberg correction for multiple comparisons) were used to establish 
differences in peptide groups and individual peptides across patient cohorts.  
Peptide abundance differences were plotted as log2FC versus –log10 BH-
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corrected p-value.  Peptides with BH-corrected p-value < 0.05 and log2FC ≥ 1 
were considered significantly upregulated, and peptides with BH-corrected p-
value <0.05 and log2FC ≤ -1 were considered significantly downregulated. The 
Tukey's HSD test was used for all pairwise comparisons.  Pairwise comparisons 
were illustrated for the major comparators of: A. Healthy vs. Mild-A, B. Healthy 
vs. Mild-B, C. Healthy vs. Moderate, D. Healthy vs. Severe, E. Mild-A vs Mild-B, 
F. Moderate vs. Severe.  Prior to statistical comparisons, these data were 
adjusted for (a) random effects by correcting in a sample dependent fashion to 
iRT peptide AUCs and sample flight number and (b) fixed effects by correcting 
for age and sex.  The peptides demonstrating differential abundance (regulated) 
in the pair-wise t-testing (BH-corrected p-value <0.05) were aggregated and 
filtered using the Matrix Annotator (http://matrisomeproject.mit.edu/analytical-
tools/matrisome-annotator/) by GO assignment for ECM.  The identification of 
regulated ECM peptides common to all or unique between AH, AUD, and healthy 
control groups were determined graphically (regulated ECM peptidome).   
 
3. Statistical analysis of renal cortex proteomic and transcriptomic data 
Statistical analyses of proteomic and transcriptomic data used one-way 
ANOVA and post-hoc t-tests corrected for multiple comparisons by the method of 
Benjamini-Hochberg, and a corrected p-value (q-value) of less than 0.05 was 
considered significant.  Analysis of immunoblot data used two-way ANOVA to 
determine interaction effects of diet (EtOH) and treatment (LPS) with post-hoc t-
test to determine significance of differences between group means with a p-value 
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≤ 0.05 considered significant.  Statistical analyses used to determine significance 
of proteins or genes with canonical pathways, gene ontological associations, and 
pathway clustering were as embedded within Ingenuity Pathways Analyses 
(analysis.ingenuity.com), MetaCore (genego.com), Gene Ontology/GO 






THE HEPATIC “MATRISOME” RESPONDS DYNAMICALLY TO INJURY: 
CHARACTERIZATION OF TRANSITIONAL CHANGES TO THE 
EXTRACELLULAR MATRIX IN MICE1 
 
A. Introduction 
Although the structural role of the ECM is well known, this compartment 
contains a diverse range of components that work bidirectionally with 
surrounding cells to create a dynamic and responsive microenvironment. This 
microenvironment, in turn, regulates cell and tissue homeostasis. ECM 
components are directly involved in signaling through interactions with cell-
surface receptors. The ECM also indirectly impacts cell-to-cell communication by 
binding and retaining soluble mediators, including cytokines, chemokines, and 
growth factors (18).  Proteases and protease inhibitors interact with the ECM to 
maintain homeostasis or respond to stress or injury.(21)  A broader definition of 
the ECM proteome (i.e., “‘matrisome”‘) has been established to encompass not 
                                            
1 Published in 93. Massey VL, Dolin CE, Poole LG, Hudson SV, Siow DL, Brock GN, 
Merchant ML, Wilkey DW, Arteel GE. The hepatic "matrisome" responds dynamically to injury: 
Characterization of transitional changes to the extracellular matrix in mice. Hepatology. 
2017;65(3):969-82. Epub 2016/12/31. doi: 10.1002/hep.28918. PubMed PMID: 28035785; 
PMCID: PMC5319876.  Reprint with permission. 
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only fibrillar ECM proteins, but also the proteins that contribute to the 
homeostasis of the ECM proteome.(18) 
In some contexts, changes to the ECM are well recognized and understood; 
for example, the formation of collagenous scars in tissue is almost a canonical 
response to unresolved chronic injury.  Hepatic fibrosis (HF) is a well-known 
example of this scarring process,(45) given that fibrotic livers develop easily 
detectable collagenous scars.  Given the dominance of these changes in the 
hepatic ECM during fibrogenesis, many studies have focused on the 
mechanisms that underlie the increases in collagen deposition.  However, the 
alterations of the hepatic ECM during fibrosis are much more diverse than simply 
an increase in collagen.  Indeed, fibrosis is characterized by changes in the 
deposition and distribution of a myriad of other ECM proteins (e.g., laminin and 
vitronectin).(111)  Whereas many of these changes are described, there are still 
gaps in our understanding.  Specifically, the magnitude and impact of these 
changes on overall liver (dys)function are incompletely understood at this time. 
ECM remodeling limited to chronic fibrogenesis, but also plays a role in early 
injury responses; the wound-healing response is a well-known example of this. 
The term “transitional tissue remodeling” describes changes to the ECM that do 
not alter the overall architecture of the organ (Fig. 3.1A).  For example, changes 
in the hepatic abundance of ECM proteins, such as fibronectin(90) and fibrin,(89, 
112) have been observed in models of hepatic inflammation.  Importantly, 
blocking these ECM changes blunts, at least in part, hepatic injury in these 
models.  Therefore, transitional changes to the ECM may contribute to early 
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disease initiation and/or progression before the onset of fibrogenesis (Fig. 3.1A). 
The nature, breadth, and magnitude of these ECM changes are currently poorly 
understood.  A better understanding could forward new mechanisms and/or 
biomarkers for diseases.  
 Although previous studies have shown that subtle changes in the ECM 
may contribute to the development of inflammatory liver injury, the research in 
this area has generally been restricted to study of single ECM proteins (e.g., 
fibrin).  (89, 112)  A proteomic approach was hindered by the challenges of low 
abundance and insolubility of many ECM proteins, until the recent development 
of a new method.  This method involves a sequential protein extraction using 
increasingly rigorous solubilization buffers along with LC-MS/MS analysis.(92, 
99, 113)  The sequential extraction was specifically designed to enrich and 
characterize ECM proteins in solid organs.  This approach also potentially 
accounts for proteins that can exist in different solubility states, based on 
posttranslational modifications (e.g., cleavage, cross-linking, and degradation). 
The goals of the current study were 2-fold: (1) to characterize the sequential 
extraction method for hepatic matrisome and (2) to compare the impact of 
inflammatory liver injury (before fibrosis) on the hepatic matrisome.  
 
B. Experimental Procedures 
1. Animals and exposures 




Figure 3.1:  Scheme of transitional ECM changes and extraction 
methodology.   
 
Remodeling in response to chronic injury (i.e., fibrosis) is well known; however, 
the hepatic ECM also responses dynamically to acute stress. These acute 
responses can be viewed as an arm of the wound‐healing response and facilitate 
recovery from damage, which resolves once the damage is repaired. However, 
under conditions of chronic injury, these changes contribute to activation of a 




























ethanol and/or LPS also as described in Chapter II.  6 control mice, 5 ethanol 
mice, 6 24h LPS mice, and 4 ethanol+24h LPS mice were used for the hepatic 
matrisome analysis.   
 
2. Three-step ECM extraction 
Liver tissue was submitted to a 3-step extraction process that allows 
sequential isolation of loosely-bound extracellular proteins, cellular proteins, 
tightly bound extracellular proteins, and highly crosslinked, insoluble proteins to 
be differentially separated as described in Chapter II.   
 
3. Sample cleanup and preparation for liquid chromatography and 
mass spectrometry 
Liver tissue extracts were prepared for LC-MS/MS analysis as described in 
Chapter II.   
 
4. Liquid chromatography and mass spectrometry 
Liver tissue extracts underwent LC-MS/MS analysis as described in Chapter 
II. 
 
5. Data analysis 
LC-MS/MS data were analyzed as described in Chapter II.   
 
6. Statistical analysis 
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Statistical analysis was performed as described in Chapter II.   
 
C. Results 
1. Analysis of changes to the ECM proteome caused by CCl4-induced 
hepatic fibrosis 
Previous studies have investigated the matrisome profile for aortic vessel and 
cardiac tissue (99, 114).  However, this method has never been employed for 
liver tissue.  The first objective of this work was to validate this multi-step 
extraction and proteomic analysis of the hepatic matrisome; toward this end, a 
model that causes robust changes to the hepatic ECM (i.e., fibrosis) was used.  
Specifically, the impact of 4 weeks of CCl4 exposure (see Experimental 
Procedures) on the ECM proteome was determined (Fig. 3.2).  As expected,(96) 
CCl4 exposure caused robust ECM deposition that was easily detected with 
standard collagen staining (Sirius Red/Fast Green; Fig. 3.2A), dot blot, and 
hydroxyproline content (Fig. 3.2B).  The proteomic approach reinforced an 
increase in collagen 1α1 abundance with CCl4 (Fig. 3.2C).  Additionally, the 
proteomic approach demonstrated that CCl4 exposure also increased abundance 
of collagens type III, IV, and V (Fig. 3.2C).   
Proteomic analysis is typically carried out on total protein extracts, as 
opposed to extracts from multi-step fractionation.  To simulate this approach, 
qualitative proteomic data from the different fractions (see Experimental 
Procedures) were pooled.  The majority of ECM proteins were detected in 




Figure 3.2: Validation of extraction technique with CCl4 model of fibrosis.   
 
Animals were injected with CCl4 or vehicle for 4 weeks.  Collagen type I 
accumulation was determined by Sirius Red staining (A) and by dot blot (control 
n=4, CCl4 n=4) and hydroxyproline content (control n=4, CCl4 n=6) (B).  
Quantitative changes in other collagens were also determined in the ECM 
extraction fractions (control n=1 pooled sample of 6, CCl4, 1 pooled sample of 5) 







exposure increased the number of ECM proteins by 7, and only one protein was 
lost compared to the control group (data not shown).  These data indicate that, 
when analyzed as a whole, there are few qualitative changes (i.e., 
disappearance or appearance of proteins) in the hepatic matrisome, even under 
conditions of significant histological ECM changes (e.g., fibrosis; Fig. 3.2A). 
 
2. Ethanol and LPS exposure cause global changes to the hepatic 
matrisome 
After validation of the multi-step extraction method with CCl4‐challenged livers 
(Fig. 3.2), a more detailed analysis of the effects of ethanol and LPS was carried 
out. Figure 3.3A shows a heatmap comparing the quantitative changes in the 
ECM proteome between the four exposure groups (±ethanol diet, ±LPS injection) 
after fractions were combined ‘in silico’; the most up‐regulated or down‐regulated 
ECM proteins were used to compare the groups. Heatmap visualization of the 
ECM proteomes demonstrates distinct segregation between the control group 
and exposure groups, with ethanol and LPS exposure groups producing varying 
patterns; ethanol + LPS produced patterns similar to both exposures alone, but 
also demonstrated unique patterns (Fig. 3.3A). However, similar to the CCl4 
qualitative analysis (see above and Fig. 3.2), ethanol and/or LPS caused only a 
small number of proteins to change qualitatively.  
 
3. Three-step serial extraction creates distinct protein profiles 
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Figure 3.3: Liver extracts have unique protein profiles based on fraction 
type and experimental group.  
 
A heatmap depicting quantitative changes to the total ECM proteome in response 
to ethanol or LPS is shown in (A).  The number of proteins unique to, or shared 
by, all four extractions of pair-fed animals is shown (B).  Bubble graphs are used 
to show presence of plasminogen, Annexin A1 and fibrin(ogen) gamma chain 








ECM proteins are not only regulated at the level of de novo synthesis, but 
also at the level of enzymatic activation, degradation, and crosslinking.  To gain 
insight into protein location and structure, previous studies have used a three‐ 
step ECM extraction method (Fig. 3.1B) in other organs.  (99, 114) Here, that 
same approach was adapted for use with liver tissue.  In the first step of this 
extraction, NaCl extraction solubilizes loosely bound proteins by displacing 
polyionic interactions. (115) Following NaCl extraction, the remaining liver tissue 
was decellularized using 1% sodium dodecyl sulfate (SDS). SDS solubilizes 
cytoplasmic and nuclear membranes, thereby releasing cellular proteins. 
Insoluble matter remaining after the decellularization then underwent extraction 
with a denaturing 4 M GnHCl buffer.(116)  Following the denaturing extraction, 
an insoluble pellet enriched in heavily cross‐linked matrix proteins 
remained.(114)  Fig. 3.3B shows a qualitative comparison of the four extracts of 
ECM proteins from control animals.  Each extract yielded a distinct ECM protein 
profile consisting of not only ECM proteins that were shared among all four 
extracts, but also proteins unique to specific extracts (Fig. 3.3B). Analysis of the 
CCl4 extracts for collagen isoforms (Fig. 3.2C) indicated that, as expected, these 
proteins tended to accumulate in the later extraction fractions. These results 
indicate that the extraction approach effectively separated ECM proteins.  
When ECM proteins were compared between experimental groups, 
interesting patterns of distribution across the extracts were revealed (Table 3.1); 
representative examples of some of these patterns are shown in Fig. 3.3C.  For 













ECM function Ref Presence of protein 
Proteoglycans and glycoproteins 
   
 
Con EtOH LPS 
EtOH 
+LPS 
Alpha-1-acid glycoprotein 1 A1AG1_MOUSE 24 Acute phase serum protein (201) NaCl  █ █ █ 
SDS     
GnHCl     
Pellet     
Alpha-2-HS-glycoprotein FETUA_MOUSE 37 Inhibitor of ECM mineralization (202) NaCl █ █ █ █ 
SDS     
GnHCl █ █ █ █ 
Pellet     
Arylsulfatase A ARSA_MOUSE 54 ECM structure (203) NaCl  █   
SDS     
GnHCl     
Pellet     
Beta-2-glycoprotein APOH_MOUSE 39 Coagulation, phospholipid 
binding 
(204) NaCl     
SDS     
GnHCl █ █ █ █ 
Pellet     
Biglycan PGS1_MOUSE 42 Regulation of collagen fibril 
formation, ECM-cell 
interactions 
(205) NaCl     
SDS     
GnHCl █ █ █ █ 
Pellet     
Corneodesmosin CDSN_MOUSE 54 Adhesive protein (206) NaCl     
SDS     
GnHCl     
Pellet █  █  
Cysteine-rich with EGF-like 
domain protein 2 
CREL2_MOUSE 38 Extracellular protein heavily 
glycosylated.  ECM 
function unknown 
(207) NaCl █ █ █ █ 
SDS     
GnHCl █ █ █ █ 
Pellet     






Decorin PGS2_MOUSE 40 ECM-cell interactions, ECM 
assembly 
(208) NaCl     
SDS     
GnHCl █ █ █ █ 
Pellet     
Dermatopontin DERM_MOUSE 24 ECM-cell interactions, ECM 
assembly 
(209) NaCl     
SDS     
GnHCl █ █ █ █ 
Pellet     
Dystroglycan DAG1_MOUSE 97 Matrix organization, basement 
membrane assembly 
(210) NaCl █ █ █ █ 
SDS     
GnHCl █ █ █  
Pellet     
Fibrinogen alpha chain E9PV24_MOUSE 87 Hemostasis, cell  signaling 
(fibrin(ogen) alpha chain) 
(211) NaCl   █ █ 
    SDS   █ █ 
    GnHCl  █ █ █ 
    Pellet    █ 
Fibrinogen beta chain FIBB_MOUSE 55 Hemostasis, cell  signaling (211) NaCl  █ █ █ 
SDS     
GnHCl     
Pellet     
Fibrinogen gamma chain FIBG_MOUSE 49 Hemostasis, fibrinogen 
polymerization 
(212) NaCl  █ █ █ 
SDS   █ █ 
GnHCl █ █ █ █ 
Pellet █   █ 
Fibronectin FINC_MOUSE 273 Scaffolding, ECM organization, 
regulation of ECM-cell 
interactions 
(213) NaCl     
SDS     
GnHCl █ █ █ █ 
Pellet     
Galectin-1 LEG1_MOUSE 15 Matrix  crosslinking, matrix 
organization 
(214) NaCl █ █ █  
SDS   █  
GnHCl █ █ █ █ 
Pellet     
Galectin-3-binding protein LG3BP_MOUSE 64 Cell-matrix adhesion (215) NaCl █ █ █ █ 
SDS  █ █ █ 
GnHCl █  █ █ 
Pellet     
          






          
Granulins GRN_MOUSE 63 Cell-matrix signaling (216) NaCl █ █ █ █ 
SDS █ █ █ █ 
GnHCl █ █ █ █ 
Pellet     
Haptoglobin HPT_MOUSE 39 Inhibition of collagen 
degradation, cell migration 
(217) NaCl █ █ █ █ 
SDS █ █ █ █ 
GnHCl █ █ █ █ 
Pellet  █ █ █ 
Insulin-like growth factor-
binding protein 2 
IBP2_MOUSE 33 Binding/retainment of ILGF in 
the extracellular  space 
(218) NaCl     
SDS     
GnHCl █ █   
Pellet     
Insulin-like growth factor-
binding protein 4 
IBP4_MOUSE 28 Binding/retainment of ILGF in 
the extracellular  space 
(218) NaCl     
SDS     
GnHCl █ █   
Pellet     
Keratin, type I cytoskeletal 13 K1C13_MOUSE 48 Cell-matrix adhesion, cell 
migration 
(219) NaCl  █  █ 
SDS     
GnHCl     
Pellet   █  
Leucine-rich HEV 
glycoprotein 
Q91XL1_MOUSE 37 Cell-matrix adhesion (220) NaCl   █ █ 
SDS     
GnHCl     
Pellet     
Lumican LUM_MOUSE 38 Regulation of collagen fibril 
formation 
(221) NaCl     
SDS     
GnHCl █ █ █ █ 
Pellet █ █  █ 
Microfibrillar-associated 
protein 5 
MFAP5_MOUSE 18 Elastic fiber assembly, binding 
of fibrillin-1 and fibrillin-2 
(222) NaCl     
SDS     
GnHCl █   █ 
Pellet     
Fibrinogen alpha chain E9PV24_MOUSE 87 Hemostasis, cell  signaling 
(fibrin(ogen) alpha chain) 
(211) NaCl   █ █ 
SDS   █ █ 
GnHCl  █ █ █ 
Pellet    █ 






          
Ribonuclease inhibitor RINI_MOUSE 50 Extracellular inhibitor of 
angiogenin which can 
degrade BM 
(223) NaCl    █ 
SDS     
GnHCl     
Pellet     
Sulfated glycoprotein 1 SAP_MOUSE 61 Cell survival, cell signaling (224, 
225) 
NaCl     
SDS █ █ █ █ 
GnHCl █ █ █ █ 
Pellet █ █ █ █ 
Syndecan-4 SDC4_MOUSE 21 ECM organization, signal 
transduction, cell adhesion 
(226) NaCl  █ █ █ 
SDS █ █ █ █ 
GnHCl █ █ █ █ 
Pellet     
Tubulointerstitial nephritis  
antigen-like 
TINAL_MOUSE 52 Protein binding - fibronectins, 
collagens 
(227) NaCl █ █ █ █ 
SDS     
GnHCl █ █  █ 
Pellet     
Vitronectin VTNC_MOUSE 55 ECM-cell signal transduction, 
cell adhesion 
(228) NaCl █ █ █ █ 
SDS     
GnHCl  █ █ █ 
Pellet     
Other ECM-associated proteins 
 
 
Con EtOH LPS 
EtOH 
+LPS 
14-3-3 protein epsilon 1433E_MOUSE 29 Protein binding (229) NaCl █ █ █ █ 
SDS     
GnHCl     
Pellet   █  
14-3-3 protein gamma 1433G_MOUSE 28 Protein binding (229) NaCl █ █ █ █ 
SDS     
GnHCl  █ █ █ 
Pellet     
14-3-3 protein sigma 1433S_MOUSE 28 Protein binding (229) NaCl     
SDS     
GnHCl     






14-3-3 protein zeta/delta 1433Z_MOUSE 28 Protein binding (229) NaCl █ █ █ █ 
SDS  █ █ █ 
GnHCl     
Pellet   █  
Actin, cytoplasmic 1 ACTB_MOUSE 42 Cortical cytoskeleton (230, 
231) 
NaCl █ █ █ █ 
SDS █ █ █ █ 
GnHCl     
Pellet █ █ █ █ 
Actin, cytoplasmic 2 ACTG_MOUSE 42 Cortical cytoskeleton (230, 
231) 
NaCl     
SDS     
GnHCl █ █ █ █ 
Pellet     
Alpha-2-macroglobulin 
receptor-    
     associated protein 
AMRP_MOUSE 42 Protein binding, soluble 
mediator internalization 
(232) NaCl █ █ █  
SDS  █ █ █ 
GnHCl █ █ █ █ 
Pellet     
Alpha-actinin-4 ACTN4_MOUSE 105 Focal adhesion,  cell adhesion (233, 
234) 
NaCl █ █ █ █ 
SDS     
GnHCl     
Pellet   █  
Annexin A1 ANXA1_MOUSE 39 ECM binding, fibrinolysis (235) NaCl    █ 
SDS     
GnHCl █    
Pellet     
Annexin A2 ANXA2_MOUSE 39 ECM binding, fibrinolysis (236) NaCl █ █ █ █ 
SDS █ █   
GnHCl     
Pellet █ █ █ █ 
Annexin A5 ANXA5_MOUSE 36 ECM binding (collagen) (237) NaCl █ █ █ █ 
SDS     
GnHCl     
Pellet     
Apolipoprotein A-I APOA1_MOUSE 31 ECM binding (collagen, 
fibronectin) 
(238) NaCl █ █ █ █ 
SDS █ █ █ █ 
GnHCl █ █ █ █ 
Pellet █ █ █ █ 
          






          
Apolipoprotein A-IV APOA4_MOUSE 45 Lipid metabolism (239) NaCl █ █ █ █ 
SDS   █ █ 
GnHCl █  █ █ 
Pellet █ █  █ 
Apolipoprotein E APOE_MOUSE 36 Lipid metabolism, cell signaling (240) NaCl █ █ █ █ 
SDS     
GnHCl █ █  █ 
Pellet     
Apolipoprotein O-like APOOL_MOUSE 29    NaCl █ █ █ █ 
SDS  █ █ █ 
GnHCl     
Pellet     
Beta-2-microglobulin B2MG_MOUSE 14 Protein binding, cell-ECM 
interaction 
(241) NaCl     
SDS █ █ █ █ 
GnHCl █ █ █ █ 
Pellet     
Calreticulin CALR_MOUSE 48 Protein binding (collagens, 
laminin)  
(242) NaCl █ █ █ █ 
SDS █ █ █ █ 
GnHCl █ █ █ █ 
Pellet     
Calumenin CALU_MOUSE 37 Pprotein binding, stabilization of 
fibulin-1 
(243) NaCl █ █ █ █ 
SDS     
GnHCl     
Pellet █ █  █ 
Carbonic anhydrase 2 CAH2_MOUSE 29 pH regulation of ECM (other 
isozymes) 
(244) NaCl █ █ █ █ 
SDS     
GnHCl     
Pellet     
Ceruloplasmin CERU_MOUSE 121 Iron, copper binding (245) NaCl  █ █ █ 
SDS     
GnHCl     
Pellet     
Chitinase-like protein 3 CHIL3_MOUSE 44 ECM turnover (246) NaCl   █ █ 
SDS     
GnHCl     
Pellet     






          
Clusterin CLUS_MOUSE 52 Extracellular protein chaperone (247) NaCl     
SDS   █ █ 
GnHCl  █ █ █ 
Pellet     
Cofilin-1 COF1_MOUSE 19 Cortical cytoskeleton,  cell 
motility 
(248) NaCl     
SDS     
GnHCl █ █ █ █ 
Pellet     
C-reactive protein CRP_MOUSE 25 Protein binding (fibronectin) (249) NaCl █ █ █ █ 
SDS  █ █  
GnHCl     
Pellet     




NaCl █ █ █ █ 
SDS     
GnHCl   █  
Pellet     
Endoplasmin ENPL_MOUSE 92 Soluble mediator (TLR  
signaling) 
(252) NaCl █ █ █ █ 
SDS █ █ █ █ 
GnHCl     
Pellet █ █ █ █ 
Estradiol 17-beta-
dehydrogenase 12 
DHB12_MOUSE 35 Protein binding (heparin, 
fibronectin, collagen) 
(253) NaCl     
SDS █ █   
GnHCl     
Pellet     
Ferritin heavy chain FRIH_MOUSE 21 Cell  migration (254) NaCl █ █ █ █ 
SDS █ █ █ █ 
GnHCl  █ █ █ 
Pellet     
Ferritin light chain 1 FRIL1_MOUSE 21 Cell migration (254) NaCl █ █ █ █ 
SDS █ █ █ █ 
GnHCl █ █ █ █ 
Pellet     
Glucose-6-phosphate 
isomerase 
G6PI_MOUSE 63 Cell motility (255) NaCl █ █ █ █ 
SDS     
GnHCl     
Pellet     






          
Hepatoma-derived growth 
factor 
HDGF_MOUSE 26 Decreted heparin-binding 
growth factor 
(256) NaCl █ █ █ █ 
SDS     
GnHCl █ █ █ █ 
Pellet     
High mobility group protein 
B1 
HMGB1_MOUSE 25 Heparin binding, cytokine (257, 
258) 
NaCl █ █ █ █ 
SDS     
GnHCl █ █ █ █ 
Pellet     
High mobility group protein 
B2 
HMGB2_MOUSE 24 Heparin binding, cytokine (257, 
258) 
NaCl  █ █ █ 
SDS     
GnHCl     
Pellet     
Lumican LUM_MOUSE 38 Regulation of collagen fibril 
formation 
(221) NaCl   █ █ 
SDS     
GnHCl     
Pellet     
Moesin MOES_MOUSE 68 Cell cortex organization (259) NaCl █ █ █ █ 
SDS     
GnHCl     
Pellet     
Myosin-9 MYH9_MOUSE 226 Cell migration, cortical actin 
organization 
(260) NaCl   █ █ 
SDS █ █ █ █ 
GnHCl █ █ █ █ 
Pellet     
Neutrophil gelatinase-
associated  
      lipocalin 
NGAL_MOUSE 23 ECM remodeling (modulation of 
MMP9 activity) 
(261) NaCl   █ █ 
SDS     
GnHCl   █ █ 
Pellet     
Nucleobindin-2 NUCB2_MOUSE 50 Matrix maturation (262) NaCl     
SDS     
GnHCl    █ 
Pellet     
Peptidyl-prolyl cis-trans  
     isomerase A 
PPIA_MOUSE 18 Matrix assembly of hensin (263) NaCl █ █ █ █ 
SDS █ █ █ █ 
GnHCl █ █ █ █ 
Pellet █  █  






          
Pro-cathepsin H CATH_MOUSE 37 Matrix degradation (264) NaCl █ █ █ █ 
SDS     
GnHCl     
Pellet     
S100-A13 S10AD_MOUSE 11 Calcium binding (265) NaCl █ █ █ █ 
SDS     
GnHCl     
Pellet     
S100-A9     NaCl  █ █ █ 
SDS █ █ █ █ 
GnHCl  █ █ █ 
Pellet     
Serum amyloid A-1  SAA1_MOUSE 14 Cell adhesion (266) NaCl   █ █ 
SDS     
GnHCl  █ █ █ 
Pellet   █ █ 
Serum amyloid A-2 SAA2_MOUSE 14 Cell adhesion (266) NaCl   █ █ 
SDS     
GnHCl  █ █ █ 
Pellet    █ 
Serum amyloid A-3 SAA3_MOUSE 14 Cell adhesion (266) NaCl     
SDS     
GnHCl   █ █ 
Pellet     




NaCl    █ 
SDS     
GnHCl     
Pellet     
Superoxide dismutase [Cu-
Zn] 
SODC_MOUSE 16 Protein binding 
(heparin/heparan sulfate,  
type 1 collage) 
(269) NaCl █ █ █ █ 
SDS █ █ █ █ 
GnHCl █ █ █ █ 
Pellet █ █ █ █ 
Thioredoxin THIO_MOUSE 12 Soluble mediator 
(immunomodulatory 
cytokine) 
(258) NaCl █ █ █ █ 
SDS     
GnHCl █ █ █ █ 
Pellet █ █ █ █ 






          
Tubulin beta-5 chain TBB5_MOUSE 50 Microtubule formation, modified 
via ECM interactions 
(231) NaCl     
SDS     
GnHCl █ █ █ █ 
Pellet     
UPF0556 protein C19orf10 
homolog 
CS010_MOUSE 18 Soluble mediator (cytokine) (270) NaCl █ █ █ █ 
SDS     
GnHCl     
Pellet     
Vimentin VIME_MOUSE 54 Microtubule formation  (271) NaCl █ █ █ █ 
SDS     
GnHCl █ █ █ █ 
Pellet █ █  █ 
Vitamin D-binding protein VTDB_MOUSE 54 Vitamin D binding (272) NaCl █ █ █ █ 
SDS █ █ █ █ 
GnHCl █ █ █ █ 
Pellet     




Con EtOH LPS 
EtOH 
+LPS 
Alpha-1-antitrypsin 1-1 A1AT1_MOUSE  46 Inhibition of ECM proteases; 
inhibition of trypsin 
(273) NaCl █ █ █  
SDS     
GnHCl  █ █ █ 
Pellet █ █  █ 
Alpha-1-antitrypsin 1-4 A1AT4_MOUSE 46 Inhibition of ECM proteases; 
inhibition of trypsin 
(273) NaCl █ █ █ █ 
SDS █ █ █ █ 
GnHCl     
Pellet     
AMBP AMBP_MOUSE 39 Precursor of protein HC 
(protein-ECM interactions) & 
bikunin (protease inhibitor),  
(274-
276) 
NaCl   █ █ 
SDS     
GnHCl █ █ █ █ 
Pellet     
Alpha-2-macroglobulin A2M_MOUSE  166 Inhibition of ECM proteases, 
inhibition of ADAMTS-7 
and ADAMTS-12 
(277) NaCl █ █  █ 
SDS     
GnHCl     






Antithrombin-III ANT3_MOUSE 52 Inhibition of ECM proteases, 
inhibition of thrombin 
(278) NaCl █ █ █ █ 
SDS █ █ █  
GnHCl  █  █ 
Pellet     
Cathelin-related 
antimicrobial peptide 
CRAMP_MOUSE 20 Inhibition of ECM proteases, 
inhibition of cathepsin L-
cysteine protease activity 
(279) NaCl  █ █ █ 
SDS   █ █ 
GnHCl  █ █ █ 
Pellet     
Cathepsin B CATB_MOUSE 37 ECM degradation (264) NaCl █ █ █ █ 
SDS    █ 
GnHCl     
Pellet     
Cathepsin D CATD_MOUSE  45 ECM degradation, activation of 
cathepsin B 
(280) NaCl █ █ █ █ 
SDS     
GnHCl    █ 
Pellet     




NaCl █ █ █ █ 
SDS  █ █ █ 
GnHCl   █ █ 
Pellet     
Complement C3 CO3_MOUSE 186 Activation of complement 
system 
(283) NaCl   █ █ 
SDS █ █ █ █ 
GnHCl     
Pellet     
Dipeptidyl peptidase 4 DPP4_MOUSE 87 Protein cleavage (cytokines, 
chemokines), protein 
binding (collagen) 
(284) NaCl     
SDS   █ █ 
GnHCl  █   
Pellet     
Ectonucleoside triphosphate 
diphosphohydrolase 5 
ENTP5_MOUSE 47 Hydrolysis of extracellular ATP (285) NaCl  █   
SDS     
GnHCl     
Pellet     
Fetuin-B FETUB_MOUSE 43 Cysteine protease inhibitor, 




NaCl █ █ █ █ 
SDS     
GnHCl     
Pellet     
          






          
Gelsolin GELS_MOUSE 86 Actin filament capping (288) NaCl █ █ █ █ 
SDS     
GnHCl   █ █ 
Pellet     
Ectonucleoside triphosphate 
diphosphohydrolase 5 
ENTP5_MOUSE  47 Hydrolysis of extracellular 
ATP/ADP (signaling) 
(286) NaCl  █  █ 
SDS     
GnHCl     
Pellet     
Hemopexin HEMO_MOUSE 51 Heme binding (289) NaCl █ █ █ █ 
SDS     
GnHCl █ █ █ █ 
Pellet     
Insulin-degrading enzyme IDE_MOUSE  118 Metalloendopeptidase (290) NaCl     
SDS     
GnHCl     
Pellet   █  
Inter alpha-trypsin inhibitor, 
heavy chain 4 
ITIH4_MOUSE 100 Chain of ITI (protease inhibitor) (291) NaCl   █  
SDS     
GnHCl     
Pellet     
Lysozyme C-1 LYZ1_MOUSE 17 Antibacterial, hydrolysis of β-1, 
4-glycosidic linkages 
(292) NaCl     
SDS     
GnHCl     
Pellet █ █ █ █ 
Lysozyme C-2 LYZ2_MOUSE 17 Antibacterial, hydrolysis of β-1, 
4-glycosidic linkages 
(292) NaCl  █ █ █ 
SDS     
GnHCl     
Pellet     
Murinoglobulin-1 MUG1_MOUSE 165 Protease  inhibitor (293, 
294) 
NaCl █ █ █ █ 
SDS     
GnHCl █ █ █ █ 
Pellet     
Myeloid bactenecin (F1) O08692_MOUSE 19 Cysteine protease inhibitor (295) NaCl  █ █ █ 
SDS  █ █ █ 
GnHCl  █ █ █ 
Pellet     






          
Phosphatidylethanolamine-
binding protein 1 
PEBP1_MOUSE 21 Serine protease inhibitor (296) NaCl █ █ █ █ 
SDS  █ █ █ 
GnHCl █ █ █ █ 
Pellet     
Plasminogen PLMN_MOUSE 91 Precursor of plasmin (serine 
protease) 
(297) NaCl     
SDS     
GnHCl  █ █ █ 
Pellet     
Probable carboxypeptidase 
PM20D1 
P20D1_MOUSE 56    NaCl █ █ █ █ 
SDS  █ █ █ 
GnHCl     
Pellet     
Serpinb9 O08797_MOUSE 42 Serine protease inhibitor, 
granzyme inhibitor) 
(298) NaCl    █ 
SDS     
GnHCl     
Pellet     
Serine protease inhibitor 
A3K 
SPA3K_MOUSE 47 Serine protease inhibitor,  
chymotrypsin inhibitor 
(299) NaCl █ █ █ █ 
SDS   █ █ 
GnHCl     
Pellet     
Serine protease inhibitor 
A3N 
SPA3N_MOUSE 47 Serine protease inhibitor,  
chymotrypsin inhibitor 
(299) NaCl   █ █ 
SDS     
GnHCl     
Pellet     
Serpin B5 SPB5_MOUSE 42 Serine protease inhibitor,  (299) NaCl     
SDS     
GnHCl     
Pellet   █  
Thioredoxin THIO_MOUSE 12 Activation of transglutaminase (300) NaCl     
SDS █ █ █ █ 
GnHCl     
Pellet     





NaCl     
SDS █ █ █ █ 
GnHCl █ █ █ █ 
Pellet     







   
  
Con EtOH LPS 
EtOH 
+LPS 





NaCl █ █ █ █ 
SDS     
GnHCl     
Pellet     
Collagen alpha-1(I) chain CO1A1_MOUSE 138 Component of collagen fibrins (303) NaCl     
SDS █ █ █ █ 
GnHCl █ █ █ █ 
Pellet █ █ █ █ 
Collagen alpha-1(III) chain CO3A1_MOUSE 139 Component  of collagen fibrils (303) NaCl     
SDS     
GnHCl █ █ █ █ 
Pellet █ █ █ █ 
Collagen alpha-1(IV) chain CO4A1_MOUSE 161 Component of collagen network (303) NaCl     
SDS     
GnHCl █ █   
Pellet █ █ █ █ 
Collagen alpha-1(V) chain CO5A1_MOUSE 184 Fibrillogenesis, crosslinking (303) NaCl     
SDS     
GnHCl     
Pellet  █   
Collagen alpha-2(I) chain CO1A2_MOUSE 130 Component  of collagen fibrils 
(contains collage-like 
domain) 
(303) NaCl     
SDS █   █ 
GnHCl █ █ █ █ 
Pellet █ █ █ █ 
Collagen alpha-2(IV) chain CO4A2_MOUSE 167 Component of collagen network (303) NaCl     
SDS     
GnHCl     
Pellet  █  █ 
Collagen alpha-2(V) chain CO5A2_MOUSE 145 Fibrillogenesis, crosslinking (303) NaCl     
SDS     
GnHCl  █   
Pellet █ █  █ 
Mannose binding protein MBL2_MOUSE 26 soluble pattern recognition  
receptor 
(305) NaCl     
SDS     
GnHCl █ █ █ █ 






Extracellular - ECM interactions unknown         
60  heat shock protein, 
mitochondrial 
CH60_MOUSE 61   
78  glucose-regulated 
protein 
GRP78_MOUSE 72   
Aminoacyl tRNA synthase 
complex-interacting 
multifunctional  
      protein 1 
AIMP1_MOUSE 34   
Arginase-1 ARGI1_MOUSE 35   
BolA-like protein 1 BOLA1_MOUSE 14   
BolA-like protein 3 BOLA3_MOUSE  12   
Carboxylesterase 1C EST1C_MOUSE 61   
Clathrin heavy chain 1 CLH1_MOUSE 192   
Epididymal secretory protein 
E1 
NPC2_MOUSE 16   
Group XIIB secretory 
phospholipase A2-like 
protein 
Q8VC81_MOUSE 22   
Heat shock cognate 71  
protein 
HSP7C_MOUSE  71   
Hepcidin HEPC_MOUSE 9   
Hypoxia up-regulated protein 
1 








IIGP1_MOUSE 48   
Lactotransferrin TRFL_MOUSE 78   
Macrophage migration 
inhibitory factor 
MIF_MOUSE 13   
Major urinary protein 12 A2CEK7_MOUSE 21   
Major urinary protein 17 MUP17_MOUSE 21   
Major urinary protein 20 MUP20_MOUSE 21   
Major urinary protein 3 MUP3_MOUSE  21   
Major vault protein MVP_MOUSE 96   
Monocyte differentiation 
antigen CD14 
CD14_MOUSE 39   
Multiple coagulation factor 
deficiency protein 2 
homolog 
MCFD2_MOUSE 16   
Myeloperoxidase PERM_MOUSE 81   
Nuclease-sensitive element-
binding protein 1 
YBOX1_MOUSE 36   
Polymeric immunoglobulin 
receptor 
PIGR_MOUSE 85   






Protein CREG1 CREG1_MOUSE 24   
Protein Gm20425 E9Q035_MOUSE  108   
Pyruvate kinase PKM KPYM_MOUSE 58   
RNA binding motif protein, 
X-linked-like-1 
RMXL1_MOUSE 42   
Serotransferrin TRFE_MOUSE 77   




PON1_MOUSE 40  
Translationally-controlled 
tumor protein 
TCTP_MOUSE 19   
UPF0369 protein C6orf57 
homolog 
CF057_MOUSE 12   
Xanthine 
dehydrogenase/oxidase 
XDH_MOUSE 147   





“absence” in response to exposures, but localized consistently to the same 
fraction when present.  Ethanol and/or LPS exposure caused other proteins to 
appear in different extracts in simple or complex patterns.  For example, whereas 
Annexin A1 was found in the insoluble pellet from control animals, it was not 
detected in any fraction from animals exposed to ethanol or LPS alone; however, 
the combination of ethanol and LPS caused this protein to accumulate in the 
NaCl fraction.  Similarly, fibrin(ogen) gamma chain was found in all experimental 
groups, but its fractionation pattern was unique to each exposure condition.  
These patterns likely represent differences in the synthesis, degradation, and/or 
maturity of the ECM proteins.   
 
4. Qualitative changes to the ECM proteome in response to stress 
Figure 3.4 summarizes the abundance of ECM proteins, organized by 
category (i.e., glycoproteins and proteoglycans (Fig. 3.4A), ECM‐associated 
proteins (Fig. 3.4B), proteases and inhibitors (Fig 3.4C), and collagens (Fig. 
3.4D)) across the four extraction conditions.  The majority of the proteins in the 
NaCl and SDS extracts were ECM‐associated proteins (Fig. 3.4A); this was 
unsurprising, given that proteins in this category are generally loosely associated 
with the ECM and are therefore easily solubilized.  Additionally, the low 
abundance of collagens in the NaCl and SDS fractions (Fig. 3.4D) was not 
surprising, given that collagens are often tightly cross‐linked and require 




Figure 3.4: Ethanol and LPS cause dynamic changes in the matrisome.   
 
The impact of ethanol diet (left panels) and 24-hour LPS (right panels) on the 
types of proteins found in the ECM proteome are shown.  Proteins are 
categorized by class (A-D) and organized by extraction fraction (NaCl, SDS, 
GnHCl, and pellet).  Red proteins indicate those that appeared with exposure, 
whereas green proteins indicate those that were lost with exposure, compared to 









created by GnHCl more than doubled the number of proteoglycans and 
glycoproteins in that extract compared to the NaCl and SDS fractions.  The 
number of collagens in the GnHCl extract was also dramatically increased 
compared to the NaCl and SDS fractions.  The pellet fraction contained the 
fewest proteins of all four extracts but contained the greatest number of 
collagens.   
Ethanol and/or LPS exposure did not change the general pattern of proteins 
found in the various extracts (Fig. 3.4), but both tended to increase the total 
number of ECM proteins in the fractions combined. For example, ethanol 
exposure caused a net increase in the number of ECM proteins by ∼25%.  These 
changes were predominantly spread across the first three protein classes, with 
the NaCl, SDS, and GnHCl extracts all increasing evenly.  The pellet fraction 
responded the least dynamically to ethanol or LPS exposure and actually 
showed a net loss in total proteins.  Likewise, collagens were the least 
responsive protein class (Fig. 3.4D).  Figure 3.5 (left panels) shows the 
distribution of the proteins in the various extracts between all four exposure 
groups.   
In addition to proteins that changed in their extraction pattern in response 
to ethanol (e.g., see Fig. 3.3C), there were several proteins that were uniquely 
detected with ethanol exposure compared to control (Figs. 3.4 and 3.5); these 
include fibrin(ogen) α and β chains, cytokeratin 13, vitronectin, plasminogen, high 
mobility group protein B2, and collagens IVα2 and Vα2 (see Table 3.1). Similarly, 




Figure 3.5: Shared and unique changes to the hepatic matrisome.   
 
Venn diagrams (left column) show all ECM proteins within each of the four 
extracts and indicate the number that are shared between, or that are unique to, 
the four experimental groups.  Bubble plots (right column) show quantitative 
changes in abundance of proteins that were shared by all four experimental 
groups.  The bubble plots show fold of control in protein abundance caused by 
LPS (y-axis), ethanol (x-axis), and the combination of ethanol + LPS (bubble 
size).  Each bubble represents a protein; bubble color indicates the protein’s 










compared to control (Figs. 3.4 and 3.5).  Several of these proteins were the same 
as those detected with ethanol exposure, but several were unique to LPS, 
including serpine B5 (maspin), serine protease inhibitor A3N, and CXC motif 
chemokine ligand 9 (see Fig. 3.5; Table 3.1).   
Previous work has shown that ethanol preexposure sensitizes the liver to 
inflammatory injury caused by a second insult (i.e., LPS) (26, 117).  Furthermore, 
previous studies have suggested that changes in ECM composition can 
contribute to the sensitizing effect of ethanol preexposure (89).  In this study, the 
combination of chronic ethanol exposure and a second hit of LPS caused unique 
changes in the ECM protein profile of the liver.  The combination of EtOH+LPS 
resulted in the appearance of four unique proteins that were not detected in livers 
from animals exposed to either ethanol or LPS alone, including serum amyloid P 
and serpine B9.   
 
5. Quantitative changes to the ECM proteome in response to stress  
Dramatic changes to the ECM (i.e., “lost” or “gained” proteins) can 
significantly affect overall organ function; it is not surprising that the majority of 
the matrisome did not change at the qualitative level.  However, several of these 
proteins did change in relative abundance in response to ethanol and/or LPS 
compared to control (Figs. 3.5 and 3.6). Figs. 3.7‐3.10 provide results of the 
clustering analysis of the protein abundances for each fraction. Based on this 
analysis, six clusters were identified as the best visual representation of the data.  




Figure 3.6: Quantitative changes to the matrisome.  
 
Heatmap analysis of the quantitative changes in abundance of proteins that were 
shared by all four experimental groups (see Fig. 3.5) are shown for the NaCl (A), 










Figure 3.7: Clustered profiles of protein abundances for proteins identified 
in the NaCl fraction.  
 
Abundance values for each protein were first standardized to a mean of zero and 










Figure 3.8: Clustered profiles of protein abundances for proteins identified 
in the SDS fraction.  
 
Abundance values for each protein were first standardized to a mean of zero and 









Figure 3.9: Clustered profiles of protein abundances for proteins identified 
in the GnHCl fraction.   
 
Protein abundances were first standardized to a mean zero and a standard 










Figure 3.10: Clustered profiles of protein concentrations for proteins 
identified in the pellet.  
 
Abundance values for each protein were standardized to a mean of zero and a 










Table 3.2: Clustering of proteins in response to ethanol and/or LPS  
NaCl fraction      
Protein  Class  Cluster  
14-3-3 protein epsilon   other ECM proteins  1  
Apolipoprotein A-I   other ECM proteins  1  
Carbonic anhydrase 2   other ECM proteins  1  
Cysteine-rich with EGF-like domain protein  proteoglycans and glycoproteins  1  
Granulins   proteoglycans and glycoproteins  1  
Hepatoma-derived growth factor   other ECM proteins  1  
Moesin   other ECM proteins  1  
Murinoglobulin-1   proteases and protease inhibitors  1  
Peptidyl-prolyl cis-trans isomerase A  other ECM proteins  1  
Antithrombin-III   proteases and protease inhibitors  2  
Dystroglycan   proteoglycans and glycoproteins  2  
Ferritin light chain 1   other ECM proteins  2  
Phosphatidylethanolamine-binding protein 1   
Serine protease inhibitor A3K   
proteases and protease inhibitors  2  
proteases and protease inhibitors  2  
Superoxide dismutase [Cu-Zn]   other ECM proteins  2  
Thioredoxin   other ECM proteins  2  
Transthyretin   proteases and protease inhibitors  2  
14-3-3 protein zeta/delta   other ECM proteins  3  
Actin, cytoplasmic 1   other ECM proteins  3  
Alpha-actinin-4   other ECM proteins  3  
Cathepsin B   proteases and protease inhibitors  3  
Cathepsin Z   proteases and protease inhibitors  3  




Haptoglobin   proteoglycans and glycoproteins  3  
Hemopexin   proteases and protease inhibitors  3  
High mobility group protein B1   other ECM proteins  3  
Pro-cathepsin H   other ECM proteins  3  
14-3-3 protein gamma   other ECM proteins  4  
Annexin A5   other ECM proteins  4  
Calumenin   other ECM proteins  4  
Endoplasmin   other ECM proteins  4  
Annexin A2   other ECM proteins  5  
Cathepsin D   proteases and protease inhibitors  5  
Glucose-6-phosphate isomerase   other ECM proteins  5  
Alpha-1-antitrypsin 1-4   proteases and protease inhibitors  6  
Calreticulin   other ECM proteins  6  
C-reactive protein   other ECM proteins  6  
UPF0556 protein C19orf10 homolog   other ECM proteins  6  
Vitamin D-binding protein   other ECM proteins  6  
Adiponectin   collagens  6  
SDS fraction      
Cysteine-rich with EGF-like domain protein 2   proteoglycans and glycoproteins  1  
Ferritin light chain 1   other ECM proteins  1  
Syndecan-4   proteoglycans and glycoproteins other 
ECM proteins  
1  
Actin, alpha skeletal muscle   2  
Apolipoprotein A-I   other ECM proteins  2  
Apolipoprotein E   other ECM proteins  2  
Collagen alpha-1(I) chain   collagens  2  
Collagen alpha-2(I) chain   collagens  2  
Granulins   proteoglycans and glycoproteins  2  
Peptidyl-prolyl cis-trans isomerase A other ECM proteins 2 Complement C3  proteases and protease 
inhibitors 3  
Ferritin heavy chain   other ECM proteins  3  
Haptoglobin   proteoglycans and glycoproteins  3  




Vimentin   other ECM proteins  3  
Sulfated glycoprotein 1   proteoglycans and glycoproteins  4  
Actin, cytoplasmic 1   other ECM proteins  5  
Calreticulin   other ECM proteins  5  
Endoplasmin   other ECM proteins  5  
Thioredoxin   proteases and protease inhibitors  5  
Beta-2-microglobulin   other ECM proteins  6  
Superoxide dismutase [Cu-Zn]   other ECM proteins  6  
Transthyretin   proteases and protease inhibitors  6  
Vitamin D-binding protein   other ECM proteins  6  
GnHCl fraction       
Alpha-2-HS-glycoprotein   proteoglycans and glycoproteins  1  
Beta-2-glycoprotein 1   proteoglycans and glycoproteins  1  
Decorin   proteoglycans and glycoproteins  1  
Ferritin light chain 1   other ECM proteins  1  
Lumican   
proteoglycans and glycoproteins 
collagens  
1  
Mannose-binding protein C   1  
Tubulin beta-5 chain   other ECM proteins  1  
Vitamin D-binding protein   other ECM proteins  1  
Actin, cytoplasmic 2   other ECM proteins  2  
Biglycan   proteoglycans and glycoproteins  2  
Fibrinogen gamma chain  proteoglycans and glycoproteins 2 Fibronectin  proteoglycans and glycoproteins 2  
Haptoglobin   proteoglycans and glycoproteins  2  
Hemopexin   proteases and protease inhibitors  2  
Myosin-9   other ECM proteins  2  
Protein AMBP   proteases and protease inhibitors  2  
Sulfated glycoprotein 1   proteoglycans and glycoproteins  2  
Vimentin   other ECM proteins  2  
Cysteine-rich with EGF-like domain protein 2   
Apolipoprotein A-I   
proteoglycans and glycoproteins  3  
other ECM proteins  4  
Beta-2-microglobulin   other ECM proteins  4  
Dermatopontin   proteoglycans and glycoproteins  4  
Galectin-1   proteoglycans and glycoproteins  4  
Granulins   proteoglycans and glycoproteins  4  




Peptidyl-prolyl cis-trans isomerase A   other ECM proteins  4  
Superoxide dismutase [Cu-Zn]   other ECM proteins  4  
Thioredoxin   other ECM proteins  4  
Collagen alpha-1(I) chain   collagens  5  
Collagen alpha-2(I) chain   collagens  5  
Syndecan-4   proteoglycans and glycoproteins  5  
Alpha-2-macroglobulin receptor-associated 
protein   other ECM proteins  6  
Calreticulin   other ECM proteins  6  
Cofilin-1   other ECM proteins  6  
Collagen alpha-1(III) chain   collagens  6  
High mobility group protein B1   other ECM proteins  6  
Phosphatidylethanolamine-binding protein 1  proteases and protease inhibitors  6  
Transthyretin   proteases and protease inhibitors  6  
Pellet fraction       
Apolipoprotein A-I   other ECM proteins  1  
Apolipoprotein E   other ECM proteins  1  
Collagen alpha-1(IV) chain   collagens  1  
Granulins   proteoglycans and glycoproteins  1  
Endoplasmin   other ECM proteins  2  
Sulfated glycoprotein 1   proteoglycans and glycoproteins  2  
Actin, alpha skeletal muscle   other ECM proteins  3  
Actin, cytoplasmic 1   other ECM proteins  3  
Annexin A2   other ECM proteins  3  
Collagen alpha-1(III) chain   collagens  4  
Superoxide dismutase [Cu-Zn]   other ECM proteins  4  
Thioredoxin  other ECM proteins 5 Collagen alpha-1(I) chain  collagens 6  






(>4‐fold increase) changes caused by LPS included ferritin heavy chain (15‐fold 
increase) in the NaCl fraction, haptoglobin and myosin‐9 (11‐ and 9‐fold, 
respectively) in the SDS fraction, and fibrinogen γ chain and haptoglobin (14‐ and 
7‐fold, respectively) in the GnHCl fraction. Likewise, ethanol exposure increased 
the abundance of several proteins, including myosin‐9 (6‐fold) and cysteine‐rich 
with EGF‐like domain protein 2 (CREDL2; 6‐fold) in the SDS fraction. As was 
observed for qualitative analysis (Fig. 3.4), ethanol and/or LPS affected proteins 
in the pellet fraction the least of all fractions.   
While ethanol alone and LPS alone each changed the abundance of certain 
proteins, the combination of the two exposures caused its own unique effects on 
the matrisome (Figs. 3.7-3.10).  For example, although LPS alone did not change 
endoplasmin abundance compared to control, and ethanol only increased it 3‐
fold, the combination of ethanol and LPS increased this endoplasmin abundance 
11‐fold in the NaCl fraction (Figs. 3.5 and 3.6).  Similarly, the combination of 
ethanol and LPS increased granulin abundance 5-fold in the SDS fraction, 
despite no effect by ethanol alone and only a 2‐fold increase by LPS (Figs. 3.5 
and 3.6).  Additionally, although both ethanol alone and LPS alone increased 
CRELD2, the combination of ethanol and LPS decreased CRELD2 abundance in 
the SDS fraction.  Proteins that were differentially regulated by the combination 







This work had two primary goals: (1) to characterize and validate an 
extraction and analysis method for the hepatic matrisome that would provide both 
the sensitivity to identify low‐abundance proteins and the power to observe global 
changes and (2) to use this method to explore transitional (i.e., prefibrotic) 
changes to the hepatic matrisome caused by ethanol diet and/or LPS exposure.  
As discussed in the Introduction, the study of the hepatic ECM has largely been 
“collagenocentric” and “fibrosocentric”—that is, centered on the dramatic 
increase in collagen deposition during fibrosis, a quasi‐permanent scarring of the 
organ.  However, the matrisome of both healthy and diseased liver is exceedingly 
more diverse than collagen ECM.  Indeed, studies have revealed that in addition 
to collagen, laminin (118) and vitronectin (119, 120) are also increased during 
fibrogenesis.  Furthermore, proteomic studies in other organs have shown that 
matrisome composition responds dynamically after insult well before organ 
fibrosis.(99, 114, 121)  Previously, this group showed that fibrin ECM 
accumulation correlates with inflammatory liver injury in several models and may 
play a causal role in hepatic damage.(89)  Additionally, Gillis et al. (90) have 
demonstrated a similar role for fibronectin ECM in experimental ALD.  However, 
global changes in the hepatic ECM during inflammatory liver injury have not yet 
been characterized.  The models herein employed (Lieber‐DeCarli ethanol diet 
and acute LPS) are well known to cause significant liver damage, but do not 
result in histologically detectable changes to the ECM. 
Global ECM changes may affect tissue function through three general types 




ECM include the matrix topography, cross‐linking, and organization.(21)  These 
physical properties are not only essential to the structural role of the ECM, but 
also allow the ECM to either obstruct or facilitate cell migration.(49)  Fibrin 
matrices have been demonstrated to be permissive to monocyte and leukocyte 
chemotaxis and activation.(122, 123)  Physical alterations in the ECM can cause 
tissue rigidity, resulting in decreased organ function.  Although such physical 
changes to the ECM can indirectly affect the biochemistry of the liver (e.g., 
hemostasis‐induced hypoxia), matrisome changes can also directly cause 
biochemical changes that are independent of structural changes.  For example, 
ECM components can facilitate ligand-receptor interactions, (124) bind and retain 
chemokines,(18) and regulate activation of growth factors (i.e., transforming 
growth factor beta). (18) ECM molecules can also directly serve as signaling 
molecules through interactions with cell‐surface receptors, including integrins. 
(125) Because of the multifaceted roles of many ECM molecules, any single 
change in the ECM can, in principle, trigger a cascade of dependent changes 
that influence the composition and properties of the ECM. For example, biglycan 
acts as a structural component that regulates collagen fiber assembly, but, upon 
release from the matrix, can act as a signaling molecule binding to Toll‐like 
receptor 4 (TLR4) receptors.(126) 
The current study determined the individual and combined effects of two 
experimental exposures (ethanol and LPS) on the hepatic matrisome.  LPS was 
selected because it induces robust hepatic inflammation.  The liver is often 




consumption.(127)  Whereas inflammatory responses triggered by small doses of 
LPS are typically noninjurious, other stresses can synergistically enhance the 
hepatotoxic response to LPS.  Indeed, ethanol not only increases circulating 
LPS, but also enhances inflammation and liver damage caused by acute LPS 
exposure.(117)  This “two‐hit” paradigm is common in fatty liver diseases.  (64)  
In the current study, both stresses caused the hepatic matrisome to respond 
dynamically, not only increasing the number of matrisome proteins , but also 
differentially changing protein abundance (Fig. 3.5) and likely structure or 
location (Figs. 3.4 and 3.5). 
Several of the protein changes reported here reiterate results of previous 
hypothesis‐driven studies. For example, this work validated that LPS dramatically 
alters the fibrin(ogen) ECM, and that ethanol preexposure enhances this effect.  
In the current study, LPS exposure increased the relative abundance of 
fibrinogen gamma chain in the GnHCl extract. The fibrin(ogen) gamma chain is a 
major component of fibrin clots given that it is polymerized into insoluble fibrin 
fibers.(128)  Therefore, the localization of this robust increase in fibrinogen 
gamma chain in the GnHCl fractions suggests that there was an increase in 
fibrin(ogen) gamma chain polymerization into a less‐soluble, more highly cross‐
linked form.  Furthermore, the combination of ethanol and LPS resulted in 
detection of the fibrin(ogen) gamma chain in the insoluble pellet, which suggests 
additional modifications that decreased solubility (e.g., cross‐linking).  The 
appearance of serum amyloid A‐1 and A‐2 proteins in response to LPS was also 




several other acute‐phase proteins, including haptoglobin, complement C, and 
ceruloplasmin, which are all known to be increased by LPS exposure. (131-133)  
This work also validates previous studies which reported ethanol increased 
fibronectin deposition before the onset of fibrosis. (90) 
The work herin also identified novel changes caused by ethanol and LPS. For 
example, previous studies have shown an association between vitronectin 
accumulation and HF/end‐stage liver disease.(119, 120)  The results of the 
current study suggest that more subtle changes in vitronectin abundance occur 
before the onset of fibrosis and hepatic decompensation.  Ethanol exposure also 
resulted in the detection of galectin‐1.  Galectin‐1 is a glycosaminoglycan‐binding 
lectin associated with cell proliferation and adhesion through modulation of 
glycoprotein cross‐linking.  Galectin‐1 may also play a role in hepatic 
inflammation and fibrinogenesis.(134)  These data suggest that ethanol and/or 
LPS likely contribute to a multitude of changes in the ECM composition, many of 
which have not yet been fully investigated. 
Changes in abundance of protease and protease inhibitors can also 
contribute to inflammatory liver injury and fibrogenesis. In the current study, 
several ECM‐associated proteases were increased in response to stress, 
including plasmin(ogen), antithrombin III, dipeptidyl peptidase, and alpha‐1‐
antitrypsin. Stress also resulted in the presence of protease inhibitors, such as 
serpine B5 (maspin) and plasminogen activator inhibitor‐1 (PAI‐1). Ethanol 
and/or LPS increased several other proteases and protease inhibitors that may 




binding protein‐1 [PEBP1], and serine protease inhibitor A2K).  These data 
support the notion that transitional remodeling of the hepatic matrisome is 
bidirectional, driven by both increased secretion of matrix proteins as well as 
altered ECM degradation. 
As mentioned above, ethanol is well known to synergize liver damage caused 
by LPS exposure.  In the current study, the combination of ethanol and LPS 
resulted in unique changes to the hepatic matrisome compared to either ethanol 
or LPS alone.  Indeed, coexposure differentially increased fibronectin and 
biglycan abundance (Fig. 3.3; Table 3.1).  Fibronectin accumulation caused by 
ethanol may contribute to hepatic inflammation through stimulation of Kupffer 
cells (KCs). (135) Biglycan is a small proteoglycan that was first recognized as a 
structural component and signaling molecule in the ECM (136).  Biglycan has 
also been implicated in inflammation, (137) possibly by retaining proinflammatory 
cytokines,(138) and/or by activating TLR4 signaling.(138)  These data suggest 
that biglycan abundance may be increased in prefibrotic stages of liver disease. 
In contrast, the combination of ethanol and LPS synergistically decreased 
PEBP1; this enzyme has been shown to inhibit trypsin‐like serine proteases, 
including thrombin, but not trypsin or tissue‐type plasminogen activator.(139)  
Multiple studies have identified PEBP1 as a critical player in metastasis (140) 
and have defined it as a metastasis suppressor gene.(141)  These changes 
represent dynamic (and potentially unique) responses of hepatic ECM to stress 




Whereas it is well established that myofibroblast‐like cells (e.g., hepatic 
stellate cells) are the primary source of fibrillar ECM during HF, most, if not all, 
hepatic cells contribute to overall matrisome homeostasis.  For example, hepatic 
sinusoidal endothelial cells are almost solely responsible for the metabolism and 
degradation of hyaluronic acid. Furthermore, stress causes inflammatory cells 
(e.g., KCs) and hepatocytes release proteases and protease inhibitors (e.g., PAI‐
1) that can affect the ECM.  Extrahepatic sources (e.g., the coagulation and 
complement cascades) can also affect the hepatic matrisome.  The ECM not only 
serves as a physical structure, but also binds/interacts with several biomolecules 
that can directly or indirectly alter responses.  For example, ECM/integrin 
interactions mediate rapid and dynamic responses to changes in the 
environment.  It is known that fibrotic ECM is known to influence cell phenotype, 
inflammation, and metastasis in the liver.(142-144)  The effects of the ECM 
changes observed here on earlier stages of liver injury should be investigated.   
In summary, the results of this work demonstrate that the hepatic matrisome 
responds dynamically to both chronic (ethanol) and acute (LPS) stresses, 
preceding more‐dramatic fibrotic changes to the liver.  It is likely that these 
transitional changes to the hepatic ECM contribute to the pathological responses 
to these stresses.  It is also interesting that several ECM proteins responded 
similarly to both stresses, suggesting a shared mechanism in both models. 
Protein changes that were unique to either ethanol or LPS exposure alone (or 




results therefore serve as a foundation for future analyses in models of liver 










AH is an acute sequela of alcoholic liver disease with a high mortality rate 
of 30-50% at 3 months and 40% at 6 months.(72, 73)  AH is characterized by 
jaundice and liver failure.(145)  AH occurs in patients with heavy chronic alcohol 
consumption (80-100 g per day) and severe ASH with or without advanced 
fibrosis and/or cirrhosis.(145, 146)  AH can be the first manifestation of clinically 
silent ALD or an exacerbation of pre-existing cirrhosis.(145)   
Accurately predicting AH patient outcome is important for clinical decision-
making.  For example, AH patients with higher risk are better candidates for 
corticosteroid treatment, and patients with lower risk could be candidates for 
long-term clinical studies.(72, 145)  While identifying AH patients at risk of liver 
inflammatory injury and failure is important, it is also difficult. Currently, the best 
approach for predicting outcome is combining static scores, such as the modified 
Maddrey’s discriminant-function, MELD, ABIC (Age, Bilirubin, INR and 




clinical scores are useful for predicting outcome in patients with severe disease, 
but are more limited in predicting outcome in patients with moderate AH.(84)   
Our group recently demonstrated significant ECM remodeling during 
inflammatory liver injury (93).  During such remodeling, peptide fragments of the 
degraded ECM increase in biologic fluids (e.g., plasma) (58). Peptidomic analysis 
of the degraded ECM (i.e., ‘degradome’) is a useful diagnostic/prognostic tool in 
metastatic cancers and other diseases of ECM remodeling (58).  
It was hypothesized that the severe inflammatory liver injury caused by AH 
would yield a unique degradome profile in human patient plasma, and that ECM 
peptides would change between patient groups.  The goals of this work are 
twofold: 1.) to identify novel candidate biomarkers for AH, and 2.) to develop new 
mechanistic hypotheses by predicting proteases that generated the observed 
degradome.   
 
B. Experimental procedures 
1. Study participants and inclusion criteria 
AH patients, AUD patients, and healthy volunteers were enrolled in the study 
as described in Chapter II.   
 
2. Study paradigm 
Relevant clinical data were collected as described in Chapter II.  As provided 
in the workflow scheme in Figure 4.1, this study was designed to analyze plasma 




or without liver injury), patients with moderate AH, and patients with severe AH 
for potential associations between parameters.   
 
3. Plasma collection 
Plasma was collected from study participants as described in Chapter II.   
 
4.  Plasma peptide purification 
Plasma peptide purification was optimized and carried out as described in 
Chapter II.   
 
5. Liquid chromatography and tandem mass spectrometry 
LC-MS/MS analysis was carried out as described in Chapter II 
 
6. Data analysis 
Peptidomic data analysis was performed as described in Chapter II. 
 
7. Statistical analysis 
Peptidomic data were log2 transformed prior to statistical analysis.  Statistical 
analysis was performed as described in Chapter II.   
C. Results 
1. Patient demographics 
A total of 114 participants including healthy volunteers (n=7) and AH (n=107) 




Figure 4.1:  Scheme of peptidomic workflow.   
 
Plasma samples were handled randomly in balanced proportions between 
groups to avoid systematic bias.  Plasma peptides were purified by TCA 
precipitation and underwent LC-MS/MS analysis with de novo spectrum 
assignment.  We identified peptides significantly changing between MELD 
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patients with AUDs having a MELD score less than 12 were assigned to the mild 
category (n=45), patients having a MELD score between 12 and 19 were 
assigned to the moderate category (n=25), and patients having a MELD score 
greater than 19 were assigned to the severe category (n=37).  The AUD/mild 
category was further subdivided into patients without liver injury (ALT<40, “Mild-
A”, n= 14) with liver injury (ALT≥40, “Mild-B”, n=31).  A variety of clinical data was 
gathered for these patients, including transaminases, alkaline phosphatase, and 
total bilirubin.  Table 4.1 shows a list of demographics and clinical data for the 
healthy, AUD (‘mild’), moderate AH, and severe AH participants.   
 
2. Plasma peptides change between MELD groups 
To visualize differences in the patients based on the peptidomic data, PCA 
was carried out (Fig. 4.2).  Principal components 1 and 2 accounted for 51.59% 
and 5.14% of the variability between the five peptidome cohorts.  PCA1 was the 
component explaining the largest set of variability (51.59%) in the data as could 
be attributed to the differences between Mild-A + Mild-B versus Moderate + 
Severe peptidomes.  PCA2 was the component explaining the second largest set 
of variability in the data (5.14%).  This component was 10-fold less than PCA1 
and could be attributed to the differences between Healthy Controls versus AH 
(Mild-A + Mild-B + Moderate + Severe).  The hierarchical clustering of the 
peptidome as grouped patient samples by similar MELD scores (Healthy Control; 




Table 4.1: Patient demographics 
 
Age 
    
Groups Healthy volunteer Mild-A* Mild-B** Moderate*** Severe*** 
# Samples 7 14 31 25 37 
# Missing 0 0 0 2 0 
Mean 28.14 40.02 44.05 49.83 48.92 
Median 26.00 37.30 44.00 51.00 50.00 
Std. Dev. 4.74 11.74 10.26 9.97 10.67 
Min. 25.00 25.30 23.19 31.00 27.00 
Max. 38.00 62.90 67.00 63.00 66.00 
      
 
AST (SGOT) (IU/L) 
    
Groups Healthy volunteer Mild-ANS Mild-B** Moderate** Severe** 
# Samples 7 14 31 25 37 
# Missing 2 0 0 2 0 
Mean 24.40 36.00 131.55 135.30 141.08 
Median 25.00 26.00 96.00 114.00 122.00 
Std. Dev. 2.88 20.00 103.71 77.66 71.26 
Min. 21.00 17.00 21.00 18.00 41.00 
Max. 28.00 87.00 388.00 347.00 370.00       
 
ALT (SGPT) (IU/L) 
    
Groups Healthy volunteer Mild-ANS Mild-B**** ModerateNS SevereNS 
# Samples 7 14 31 25 37 
# Missing 2 0 0 2 0 
Mean 20.40 27.57 97.68 59.78 48.95 
Median 17.00 27.00 83.00 46.00 40.00 
Std. Dev. 5.18 8.05 59.31 45.63 30.11 
Min. 16.00 14.00 40.00 15.00 12.00 





    
Groups Healthy volunteer Mild-ANS Mild-BNS Moderate*** Severe*** 
# Samples 7 14 31 25 37 
# Missing 2 0 0 2 0 
Mean 48.80 68.50 93.52 175.91 180.65 
Median 54.00 64.50 91.00 147.00 157.00 
Std. Dev. 10.92 27.05 25.62 109.32 83.90 
Min. 37.00 44.00 56.00 41.00 72.00 




      
 
Bilirubin (mg/dL) 
    
Groups Healthy volunteer Mild-ANS Mild-BNS Moderate* Severe**** 
# Samples 7 14 31 25 37 
# Missing 2 0 0 2 0 
Mean 0.52 0.86 0.74 7.22 18.31 
Median 0.50 0.60 0.60 5.10 18.20 
Std. Dev. 0.13 0.93 0.57 7.66 7.69 
Min. 0.40 0.20 0.20 0.60 4.70 
Max. 0.70 4.00 2.60 35.00 34.20       
 
Albumin (g/L) 
    
Groups Healthy volunteer Mild-ANS Mild-BNS Moderate**** Severe**** 
# Samples 7 14 31 25 37 
# Missing 2 0 0 2 0 
Mean 4.06 4.03 4.17 2.77 2.51 
Median 4.20 4.10 4.20 2.80 2.40 
Std. Dev. 0.31 0.34 0.50 0.68 0.46 
Min. 3.60 3.20 2.60 1.70 1.60 
Max. 4.40 4.50 5.20 4.50 3.50       
Sex 
     
Groups Healthy volunteer Mild-AND Mild-BND ModerateND SevereND 
# Samples 7 14 31 25 37 
# Missing 0 0 0 2 0 
# Males 1 7 26 15 24 
# Females 6 7 5 8 13       
Ascites 
     
Groups Healthy volunteer Mild-AND Mild-BND ModerateND SevereND 
# Samples 7 14 31 25 37 
# Missing 0 0 0 3 0 
# None 7 14 30 11 5 
# 
Mild/Moderate 
0 0 1 11 25 
# Severe 0 0 0 0 7       
Plasma color 
     
Groups Healthy volunteer Mild-AND Mild-BND ModerateND SevereND 
# Samples 7 14 31 25 37 
# Missing 0 1 2 11 10 






0 0 2 0 0 
# Light red 0 0 1 0 0 
# Dark yellow 0 0 0 12 23 
# Orange 2 0 0 1 3 
# Red orange 0 0 0 0 1 
# Red 0 1 0 0 0 
 
ND- not determined 








Figure 4.2: Multivariate analysis of the plasma peptidome using principal 
component analysis biplots and heat maps with hierarchical clustering.   
Patient differences for different AH severity groups based on peptidome were 
visualized using (Fig 5A) PCA and heat maps with hierarchical clustering (Fig 
5B).  PCA was carried out for significantly changed peptides (BH corrected p-
value <0.05) using a linear mixed model approach. “Age” and “Sex” were 
considered fixed variables, and “Flight” and iRT1-11 peptide standards were 















 peptides .  The first cluster was interpreted as peptide abundances in order of 
HC > Mild-A = Mild-B > Moderate = Severe.  The second cluster was interpreted 
as peptides abundances in order of Mild-A = Mild-B > HC = Moderate = Severe.  
The third cluster was interpreted as peptide abundances in order of Moderate = 
Severe > HC > Mild-A = Mild-B; thus each disease severity stage yielded a 
unique peptidome pattern (Figure 4.3).   
 Linear discriminate modeling of the cohort peptide abundances following 
adjustment for age, sex, iRT internal standards, and sample analysis flight 
identified 12-497 differentially regulated peptides (Table 4.2).  These pairwise 
differences were in agreement with PCA loading comparisons demonstrating 
very small numbers of significantly regulated peptides between Mild-A and Mild-B 
while large differences between HC and each AH cohort member.  Individual 
pairwise comparisons by volcano plots were used to illustrate peptides that are 
differentially abundant by both statistical significance and fold change (Figure 
4.3). 
 
3. ECM peptides change between MELD groups 
To address the working hypothesis that surrogate markers of AH would be 
associated with altered matrisome metabolism, the regulated peptides (q-value 
<0.05) identified from the iterative pairwise comparisons of Healthy Control (HC) 
versus AH cohort (Mild-A, Mild-B, Moderate and Severe) as well as the 













Healthy volunteer vs. 
Mild-A 
497 130 301 
Healthy volunteer vs. 
Mild-B 
392 112 226 
Healthy volunteer vs. 
Moderate 
207 32 152 
Healthy volunteer vs. 
Severe 
344 109 205 
Mild-A vs Mild-B 12 1 1 





Figure 4.3: Pairwise comparison of the peptidomes of patients with 
different AH severity by volcano plots.   
 
Peptide abundance differences were plotted as log2 of the fold-change versus –
log10 BH-corrected p-value.  Peptides with BH-corrected p-value < 0.05 and 
log2FC ≥ 1 were considered significantly upregulated, and peptides with BH-
corrected p-value <0.05 and log2FC ≤ -1 were considered significantly 
downregulated. The Tukey's HSD test was used for all pairwise comparisons.  
Pairwise comparisons were illustrated for the major comparators of: A. Healthy 
vs. Mild-A, B. Healthy vs. Mild-B, C. Healthy vs. Moderate, D. Healthy vs. 













a spreadsheet.  The gene names associated with each differentially regulated 
peptide were submitted for annotation by matrisome category and division using 
the matrix-annotator tool at the MIT Matrisome project website 
(http://matrisomeproject.mit.edu/analytical-tools/matrisome-annotator/).  These 
gene names were annotated by the matrisome-annotator tool as a component of 
the core matrisome (collagen, ECM glycoprotein, proteoglycan) or the matrisome 
associated compartment (ECM regulators, ECM-affiliated proteins, secreted 
factors). The regulated ECM peptidome (Table 4.3) by absolute numbers were 
ranked in the following order: (HC versus Mild-A or Mild-B) >>> (HC versus 
Moderate or Severe) >>> (Moderate versus Severe) or (Mild-A versus Mild-B).  
These data suggest that the plasma peptidome may be able to discretely 
differentiate HC versus Mild AH and Moderate versus Severe AH.  
The regulated ECM peptides for the HC versus AH cohorts (Mild-A, Mild-B, 
Moderate, and Severe) were compared by Venn Diagram (Fig. 4.4 inset) and 
regulated peptides to all four comparisons were identified.  The annotation of 
these gene names by matrisome-annotator identified 4 ECM peptides out of 101. 
These four peptides included: one peptide derived from collagen (I) alpha 2 
labeled as COL1A2-394 with the sequence 
612SGP(OH)PGPDGNKGEP(OH)GVVGAVGTAGP635, two peptides from 
fibrinogen alpha chain FGA-649 (426REYHTEKLVTSKGDKEL442), FGA-1238 
(581KQFTSSTSY589), one peptide SRGN-392 from serglycin 



































Total Peptides 497 392 207 344 12 94 







9 (75) 23 (24) 
















2 (17) 67 (71) 
  -Collagens 104 59 21 81 0 52 
  -ECM Glycoproteins 118 107 6 39 2 14 
  -Proteoglycans 4 3 4 7 0 1 
Matrisome-associated 25 (5) 16 (4) 4 (2) 13 (4) 1 (8) 4 (4) 
  -ECM Regulators 24 16 4 11 1 4 
  -ECM-affiliated 
Proteins 
1 0 0 1 0 0 








Figure 4.4: Regulated peptides common to HC to AH pairwise comparisons 
include ECM peptides.   
 
Regulated peptides were identified using data from volcano plots of HC vs. Mild-
A, HC vs. Mild-B, HC vs. Moderate, and HC vs. Severe were compared by Venn 
diagram analysis (inset).  Peptides common to all comparisons (n=101) were 
annotated for GO and the relative fold difference of the HC to AH-cohort plotted 





















































































































C O L 1 A 2 -3 9 4
F G A -6 4 9
F G A -1 2 3 8
S R G N -3 9 2






245RPPGFSP251 (also known as bradykinin 1-7).  As illustrated in Figure 4.4, two 
peptides (COL1A2-394, SRGN-392, and KNG1-123) increased with AH severity, 
one peptide (FGA-1238) decreased with AH severity and two peptides (FGA-649 
and SRGN-392) were reduced across all AH cohorts and did not change with AH 
severity. These data demonstrate the response of select matrisome 
compartments across the AH spectrum. 
 
D. Discussion 
AH is a diagnosis of acute hepatic inflammation and liver failure based on 
AST, AST/ALT, serum bilirubin, INR, neutrophilia, ascites, and history of 
AUD.(72)  AH has a 3-month mortality rate of 30-50%.(73)  Both AH diagnosis 
and prognosis could be impacted by the development of more sensitive and 
specific biomarkers.  Our group previously demonstrated that inflammatory stress 
causes the hepatic ECM to undergo dynamic transitional remodeling.(93)  Others 
have shown that ECM remodeling causes degradation products to be secreted 
into blood and that analysis of these peptides (i.e. the ECM degradome) is a 
useful prognostic tool in diseases that involve ECM remodeling.(58, 59)  
Therefore, the work in this pilot study aimed to test the hypothesis that the 
plasma ECM degradome changes with AH severity. 
To this end, peptides were purified from AH patient plasma and analyzed 
using LC-MS/MS.  Internal standards (non-human peptides, iRT, Biognosis USA, 
Beverly, MA) spiked into samples enabled normalizing of day-to-day instrument 




Patients were divided into groups based on AH severity (MELD score) and the 
changes in the peptidome patterns across groups were examined with 
multivariate analyses, considering age and sex as fixed variables, and flight and 
the 11 peptide standards as random variables.  The PCA approach to data 
analysis is based on data reduction and collapses all data points within a sample 
into a single x,y coordinate. This approach allowed for an unbiased self-sorting at 
the patient level, not the discrete peptide level, based on the intrinsic nature of 
the data. These data demonstrated that differences in the peptidome can 
separate patients by AH severity group.  Principal component 1, which accounted 
for 51.59% of variability in the data, generally separated Mild-A and Mild B from 
Moderate and Severe, with the Healthy group in the middle.  Principal component 
2, which accounted for 5.14% of variability in the data, appeared to separate 
healthy patients from all AH patients.  PCA showed little difference between Mild-
A and Mild-B or between Moderate and Severe.  The subsequent multivariate 
approach for modeling the peptidome data was hierarchical clustering with heap 
maps grouping the relative peptide abundances into unique patterns in the 
peptidome between AH severity groups.  The hierarchical clustering of the 
complete dataset identified three strong groupings of peptide abundance patterns 
that reflected combinations of (A) increased peptide levels in healthy controls, (B) 
increased peptide levels in Moderate + Severe and (C) increased peptide levels 
in Mild-A + Mild-B AH cohorts.  These data supported the justification to conduct 
pair-wise comparisons of the mean peptide differences between HC and AH 




relative abundance changes in ECM peptides with strong differences noted in the 
collagen and fibrinogen peptides.  Consistent with the multivariate analysis, the 
largest changes in the peptidome were observed between mild vs. healthy and 
severe vs. healthy.  While each pairwise comparison is heavily dominated by 
ECM fragments, the regulated peptides common to all HC to AH comparisons 
only contained 5 ECM peptides out of a possible 101.  While these pilot data 
provide strong evidence that altered ECM turnover is associated with the AH 
spectrum additional research is required to confirm these findings. 
While the sample handling, sample analysis and statistical modeling 
integrated methods for sample handling randomization, inclusion of internal 
standards and statistical modeling to account for random or fixed effect variables 
there are still several limitations to these studies that should be noted. The 
balance of HC to AH cohort is imbalances in “n” values and this may be 
insufficient to adequately power the study.  Additionally, the potential for a 
“clinical site effect” is present.  The HC plasma samples were recruited at the 
University of Louisville.  The Mild-A and Mild-B plasma samples were recruited at 
the NIH-NIAAA.  The Moderate and Severe plasma samples were recruited at 
the University of Louisville, the University of Massachusetts Medical School, the 
University of Texas-Southwestern and the Cleveland Clinic.  Therefore, the 
potential for a “clinical site effect” is present.  Despite these study limitations the 
statistical modeling and informatics filtering of the peptidomics data supports the 




These patterns of select peptidome “features” can be investigated further in 







CHRONIC MODERATE ALCOHOL CONSUMPTION INFLUENCES RENAL 
CORTICAL OXIDANT RESPONSE PATHWAYS 
 
A. Introduction 
Ethanol (EtOH) is arguably the most common substance voluntarily 
consumed at toxic doses by humans.  Pharmacologically relevant concentrations 
of EtOH affect multiple organs,(148, 149) and EtOH consumption is a known risk 
factor in over 200 health conditions (9).  Despite this knowledge, the ability to 
reverse EtOH-induced organ damage or predict at-risk individuals for EtOH-
induced organ damage is limited even in well-known target organs (e.g. the liver) 
(150).  In contrast to the liver, it is unclear if the kidney is a direct target of EtOH 
toxicity. Heavy EtOH consumption is well recognized to be associated with 
enhanced risk for renal failure secondary to hepatic cirrhosis, a phenomenon 
known as hepatorenal syndrome (HRS) (151). Renal failure associated with HRS 
is a complication in 14.4% of AH patients having MELD scores ≥22 (152).  The 
widespread view that this renal failure is strictly secondary to hepatic cirrhosis 
with no role for direct EtOH nephrotoxicity may largely be an artifact of clinical 
charting, as was the case for alcoholic pancreatic damage (153).  Moderate 




disease (154), and connections between alcohol use disorders and kidney 
damage are controversial (155).  Studies on moderate EtOH consumption have 
shown EtOH to be (1) inversely associated with development or progression of 
chronic kidney disease (85, 95, 156, 157) and (2) associated with improved 
outcomes in renal transplant patient populations (158, 159).  However, these 
studies were not specifically designed to address the question as to whether or 
not EtOH consumption damages the kidneys, and a mechanistic explanation for 
these observations has not been explored. Overall, a more in-depth investigation 
is justified to discern both the direct and indirect effects of EtOH on the kidney. 
Rodent studies have identified detrimental effects of EtOH to kidney at the 
tissue and subcellular, including increased tissue markers of oxidative damage 
and myeloperoxidase expression in rats (87) and increased Cyp2e1 
induction(88), and mitochondrial protein hyper-acetylation in mice (86). These 
investigations have been driven by the hypothesis that the effect of EtOH on the 
kidneys mirrors its effects on the liver. Confirmation of these parallel mechanisms 
between these two organs may be due to similarities in expression of EtOH 
metabolizing enzymes Cat and Cyp2e1. However, while the liver and kidney are 
the major organs for EtOH detoxification, significant differences in structure, 
function, and parenchymal composition exist.  
We used discovery-based proteomic and transcriptomic approaches to study 
the effects of EtOH on the renal cortex and secondarily the effects of EtOH pre-
exposure on the response (4h and 24h) to LPS (10mg/kg i.p.).  Integrated IPA 




signaling pathways including decreased activation of the Nuclear factor 
(erythroid-derived 2)-like 2 (Nrf2)  and increased activation of the aryl 
hydrocarbon receptor (Ahr) oxidative stress responses pathways. These studies 
suggested an EtOH-dependent, selective dysregulation of cortical oxidant 
response pathways.   
 
B. Experimental procedures 
1. Animals and exposures 
Mice were exposed to chronic ethanol and/or LPS as described in Chapter II.  
Mice were exposed to chronic ethanol and/or ethanol binge as described in 
Chapter II.   
 
2. Histology and immunohistochemistry 
Renal cortex tissue was stained with PAS as described in Chapter II.  IHC for 
Mpo and Cat was conducted on renal cortex tissue as described in Chapter II.   
 
4. Blood urea nitrogen analysis 
BUN in mouse plasma was determined using a standard kit as described in 
Chapter II. 
 
5. Proteomic sample handling 
3 control mice, 3 ethanol mice, 3 4h LPS mice, and 3 ethanol+4h LPS mice 




renal cortex tissue, digested, labeled, and prepared for LC-MS/MS analysis as 
described in Chapter II.  
 
6. Liquid chromatography and tandem mass spectrometry 
1D-LC-MS/MS analysis and subsequent data analysis were carried out as 
described in Chapter II 
 
7. RNA seq analysis 
3 control mice, 3 ethanol mice, 3 4h LPS mice, and 3 ethanol+4h LPS mice 
were used for the renal cortex transcriptomic analysis.  The same mice were 
used for the renal cortex proteomics and transcriptomics, except for 1 4h LPS 
mouse and 1 ethanol+4h LPS mouse that were different.  RNA was isolated from 
renal cortex sections and RNA Seq analysis was carried out as described in 
Chapter II.  RNA Seq data were analyzed as described in Chapter II.   
 
8. Multivariate analysis of proteomic and transcriptomic data 
Multivariate analysis of proteomic and transcriptomic data was completed as 
described in Chapter II. 
 
9. Immunoblot analysis 
Western blot analysis was carried out on protein extracted from renal cortex 
tissue as described in Chapter II.  Primary antibodies against Nqo1, Sod1, Sod2, 





10.  Statistical analyses 
Statistical analyses of proteomic and transcriptomic data were carried out as 
described in Chapter II.   
 
C. Results 
1. Ethanol, LPS, and the combination increase blood urea nitrogen  
The Lieber-DeCarli model (Fig. 5.1A) of chronic moderate EtOH consumption 
was used to examine the effects of EtOH ± LPS on the kidneys of male mice.  
This is an established model that causes early alcohol-induced liver injury and 
sensitizes the liver to a subsequent inflammatory insult, such as LPS.(93).  
Ethanol consumption caused a small but significant increase in BUN levels 
(p<0.05) in mice in the absence of an LPS challenge (Fig. 5.1B).  LPS injection 
significantly increased BUN levels (p<0.005) 24h after injection; ethanol exposure 
did not significantly alter the increase in BUN caused by LPS administration.   
 
2. Ethanol alone contributes little-to-no morphological changes to 
mouse renal cortex 
Analysis Hematoxylin and Eosin- (H&E, not shown) and PAS-stained (Fig. 
5.2) tissue sections identified mild proximal tubular brush border loss with LPS 
and increased infiltration of polymorphonuclear leukocytes (PMNs, as noted by 




Figure 5.1: Effects of chronic moderate EtOH feeding and low dose 
(10mg/kg intra-peritoneal (i.p.) lipopolysaccharide (LPS) on blood urea 
nitrogen (BUN).   
(A) To model chronic moderate EtOH consumption the Lieber DeCarli diet model 
of a four week escalation followed by a two week hold at 6% EtOH in the liquid 
diet was used. Control animals received a isocaloric substitute of maltose-dextrin 
in the liquid diet.  A LPS (10mg/kg) LPS or saline injection given i.p. either 4h or 
24h prior to sacrifice. (B) Baseline differences in BUN were observed with EtOH 
feeding as well as an LPS effect at 24h.  Statistical differences were determined 














































Figure 5.2: Mild effects of EtOH and/or LPS on renal architecture.   
Histologic evaluation by periodic acid-shiff (PAS) stain (100x) demonstrates 
unremarkable effects on renal parenchymal architecture of control (left column, 
n=3) versus EtOH fed (right column, n=3) animals.  Following low-dose 
(10mg/kg) i.p. LPS renal cortical sections demonstrate low to moderate levels of 
tubular dilation, vacuolization, brush border loss and PMN infiltration at 4h 
(middle row) and 24h (bottom row). Glomerular infiltration by 














in kidneys from mice exposed to EtOH versus control or EtOH + LPS versus LPS 
alone, suggesting at the gross level there was no need for tissue scoring of 
kidney histology. 
 
3. Ethanol attenuates LPS-induced cortical recruitment of MPO-positive 
cells  
Although gross histology was unaffected by exposure regimen, the PAS stain 
demonstrated that LPS exposure increased the number of infiltrating neutrophils 
and caused brush border loss both 4 and 24h after challenge in the EtOH and 
control cohorts.  Based on quantitative IHC, control and EtOH-fed mouse kidneys 
were similar and unremarkably different for Mpo staining (Fig. 5.3).  LPS induced 
a strong, significant recruitment of Mpo-positive cells into the cortex.  Moreover, 
EtOH significantly attenuated the recruitment of Mpo-positive cells caused by 
LPS at 4h but not 24h post-injection (Fig. 5.3). 
 
4. Ethanol and LPS each cause unique protein abundance patterns. 
Proteomic analysis of TMT 10-plex labeled cortical digests (Fig. 5.4A) 
resulted in identification of over 2,400 proteins (Fig. 5.4B) by two or more 
peptides.  Chronic, moderate EtOH consumption increased the abundance of 22 
proteins and decreased the abundance of 70 proteins (Fig. 5.4C).  Significant 
protein abundance changes in the LPS compared to control animals were 
greatest at 24h (108 increased, 10 decreased) compared to 4h-post LPS 




Figure 5.3: LPS induced infiltration of myeloperoxidase (MPO) positive 
cells into the renal parenchyma.   
(A) Infiltration of MPO positive cells was quantified by IHC staining and counting 
of MPO-positive cells (40x) in glomerular (→) and tubular (→) compartments 
(33±4 visual fields per kidney section).  (B) Infiltration was significantly increased 
at both 4h (n=3) and 24h after LPS (n=3), compared to baseline (n=3).  There 
was significant difference between control (n=3) and EtOH fed animals (n=3) at 
4h post low dose LPS i.p. challenge.  Statistical differences were determined 
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Figure 5.4: Workflow and characterization of the global effect of EtOH and 
LPS on the cortical proteome.   
Using a TMT workflow (5.4A) the renal proteomic dataset included 2,487 proteins 
(>98% at ≥2-peptide level, (5.4B) detected with high confidence.  Differences of 
relative abundance are shown as Log2 fold change (FC) and are evaluated in 
volcano plots (5.4C-G) with a FC >1.2 and corrected ANOVA p-value<0.05 
considered significant. As a primary hit, the effects of EtOH and LPS are 
comparable in magnitude. This time dependent effect was maintained (5.4F-G) 
with the two-hit comparison of EtOH on an LPS background (EtOH+LPS versus 
LPS) with smaller differences observed by log2 FC (EtOH+4hLPS to 4hLPS) 



































































































































































value) <0.05) trends in protein abundance fold-changes (Log2FC>0.5 or 
Log2FC<-0.5) with larger fold changes between two or more conditions.  A four 
protein grouping (Ehhadh, Acad11, Sqstm1, and Hnrnpc) had diminished 
abundance with EtOH versus control (Fig. 5.5A, dotted box) but the differences 
were normalized at 4h- and 24h-post LPS.  A second grouping of ribosomal 
proteins  (Rpl6, Rpl8, Rpl13a, and Rps15) had increased abundance in EtOH-fed 
animals on a background of 24h LPS (Fig. 5.5B, dotted box). 
 
5. RNA seq data support proteomic data for LPS effect. 
To study the early two-hit effects of EtOH ± LPS, the RNA were isolated from 
EtOH, control, 4h LPS and EtOH+4h LPS animals only.  The RNA integrity 
number (RIN) values for RNA isolated from mouse kidneys averaged 7.8 ± 0.5. 
Following ribosomal depletion, RNA library preparation and high throughput 
sequencing, a total of 47,719 transcripts were observed including 24,405 
detected in all samples.  Of 47,719 detected transcripts, EtOH increased the 
expression of 88 and decreased the expression of 99 (Fig. 5.6D/Table 5.1A).  
LPS increased the expression of 1,468 and decreased the expression of 911 
transcripts (Fig. 5.6E/Table 5.1A).  Hence, 4h LPS, compared to EtOH, induced 
approximately a 10-fold increase of differentially abundant transcripts relative to 
the control animals (Fig. 5.6E-G).  As shown in Table 1, EtOH significantly (q ≤ 
0.05; Log2FC≥1) altered the expression of six (6) transcripts apparently 




Figure 5.5: Quantitative cluster analysis reveals EtOH-regulated protein 
clusters.   
Log2 FC values are plotted relative to the pooled internal standard reporter ions.  
(A) EtOH-dependent, LPS-independent protein abundance changes.  Significant 
differences (q-value <0.05) were observed for a protein cluster in control versus 
EtOH (black dotted boxes).  (B) EtOH-dependent and late (24h) low dose LPS 
protein abundance changes of ribosomal-related gene product cluster.  
Significant differences (q-value <0.05) were observed for LPS 24h versus EtOH 
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6. Ethanol alone downregulates Nrf2-mediated oxidative stress 
response pathways at the protein level and transcript level. 
A multivariate comparison by IPA of the top-20 canonical signaling pathways 
for the proteome and transcriptome by single-hit (EtOH compared to control, 
4hLPS compared to control) and two-hit comparisons (EtOH + 4h LPS compared 
to 4h LPS; EtOH +4h LPS compared to EtOH) are shown in Fig. 5.5A.  The 
effects of EtOH feeding ± LPS exposure on signaling pathways (Fig 5.5A) or 
individual protein abundance levels (Fig 5.5B) are illustrated as heat maps.  
Heat-map colors are assigned dichotomously to illustrate activation (positive Z-
score, red/orange) or inactivation (negative Z-score, green/blue) based on the 
Log2 relative abundance changes for proteins or transcripts within the pathway 
as previously discribed.(160, 161)  Six overlapping canonical pathways (noted by 
asterisks) for EtOH alone include effects on cell-cell interactions, oxidant stress 
response, actin reorganization, protein unfolding stress response and protein 
translation.  
 In the EtOH vs. control comparison for both the proteomic and 
transcriptomic analyses, Ahr signaling had a positive z-score (i.e. overall pathway 
activation) largely due to decreased abundance of heat shock protein 90-α and –
ß proteins, increased abundances Ahr-targets Nqo1, Aldh isoforms and Gst 
enzymes.  Nrf2-mediated oxidative stress response canonical pathway had a 
negative z score (i.e. overall pathway deactivation, Fig. 5.7A-B) due to large 
decreases in Nrf2 targets such as Sod1, Sqstm1/p62, and Gclc.  LPS caused 




Figure 5.6: Workflow and characterization of the EtOH and 4h LPS 
regulated transcriptomes.   
Of 47,719 detected transcripts (36,571 in Venn Diagrams) after filtering for 
corrected p-value (Benjamini-Hochberg q-value <0.05), (D) EtOH increased the 
expression of 88 (red points) and decreased the expression of 99 (green points). 
(E) LPS increased the expression of 1,468 (red points) and decreased the 
expression of 911 (green points) transcripts. (F) EtOH on a background of 4h 
LPS increased the expression of 79 (red points) and decreased the expression of 
















































































































Table 5.1: Effects of EtOH and LPS on differentially regulated cortical RNA 
transcripts, differentially regulated genes, and one-hit/two-hit associated 












p ≤ 0.05  q ≤ 0.05 p ≤ 0.05  q ≤ 0.05; logFC≥1
EtOH Control 187 (88↑, 99↓) 66 (22↑, 44↓)
4h LPS Control 2379 (1468↑, 911↓) 1814 (1141↑, 673↓)
EtOH+4h LPS EtOH 2695 (1538↑, 1157↓) 1842 (1114↑, 728↓)
EtOH + 4h LPS 4hLPS 147 (79↑, 68↓) 135 (68↑, 67↓)
Regulated Transcripts: Treatment versus Control (One-hit)
Treatment GO Term Description Genes q-value
EtOH
response to interferon-gamma 2 0.011
skeletal muscle tissue development 3 0.012
innate immune response 5 0.012
regulation of body fluid levels 4 0.014
skeletal muscle organ development 3 0.014
4h LPS
innate immune response* 146 8.43E-50
response to cytokine* 130 4.94E-36
regulation of cytokine production* 128 1.96E-34
defense response to other organism* 123 4.76E-34
positive regulation of cytokine production 97 4.24E-31
Regulated Transcripts: Treatment versus [EtOH + 4h LPS] (Two-hit)
Treatment GO Term Description Genes q-value
EtOH
innate immune response* 149 4.34E-51
response to cytokine* 140 6.71E-42
defense response to other organism* 122 1.22E-32
regulation of cytokine production* 126 2.18E-32
cellular response to cytokine stimulus 107 1.08E-29
4h LPS
positive regulation of smooth muscle cell proliferation 6 6.24E-06
positive regulation of cell migration 11 1.42E-05
positive regulation of cell motility 11 1.91E-05
wound healing 10 2.16E-05
positive regulation of cellular component movement 11 2.37E-05
DEG Expression Regulation Trends (q ≤ 0.05; logFC≥1)
































and the LXR/RXR activation pathway, whether or not mice were fed an EtOH 
diet.   
 
7. Effects of ethanol and LPS on catalase abundance. 
Cat IB analysis confirmed proteomic findings, demonstrating a significant (2-
way ANOVA, *p-value<0.05) decrease of approximately 40-50% in the renal 
cortical tissue of EtOH fed mice with an insignificant LPS-effect (Fig. 5.10A-B). 
Additional Cat IB analyses lysates from a chronic-plus-binge study of alcohol 
feeding demonstrated similar effects on Cat abundance following 10-day EtOH 
feeding or, strikingly, 9h post-EtOH gavage (Fig. 5.10C). This data suggested the 
effect of EtOH on Cat abundance was not associated with the chronicity of EtOH 
feeding, IB.   
 
8. Data Sharing 
Proteomic files including acquired LCMS data (.RAW), search engine files 
(.mgf), and search results aggregated into a Scaffold3 (.sf3, 
ProteomeSoftware.com) have been deposited with MassIVE 
(http://massive.ucsd.edu/) data repository with the Center for Computational 
Mass Spectrometry at the University of California, San Diego (MSV000083053) 
and shared with the ProteomeXchange (www.proteomexchange.org) 




Figure 5.7: | Effects of EtOH feeding on Cat abundance in the renal cortex.   
Cat immunoblot analysis (A) demonstrates a significant reduction of Cat protein 
with EtOH feeding (n=3) compared to control (n=3) without LPS administration 
(two-way ANOVA *p-value<0.001).  IHC staining (10X) for Cat (B) demonstrated 
comparable EtOH-associated decreases in the cortical tissue 
(cortical/juxtamedullary boundary noted by red dashed line) of LPS-naïve (n=3) 
mice compared to control (n=3) and LPS-challenged mice (n=3) compared to 
LPS alone (n=3).  (C) Similar EtOH effects on Cat abundance were observed 
using a separate more severe model of EtOH feeding (NIAAA chronic plus binge 
model; control n=3, chronic EtOH n=3, EtOH gavage n=3, chronic EtOH+EtOH 
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results have been deposited with the NCBI Gene Expression Omnibus (162) 
(https://www.ncbi.nlm.nih.gov/geo) as the study GSE81947.   
 
D. Discussion 
Ethanol consumption is a risk factor in numerous health conditions, yet it is 
still unclear if the kidney is a direct target of EtOH toxicity. Hypothesis-driven 
studies on the effects of EtOH consumption on renal parenchyma are limited.  
We hypothesized that chronic, moderate EtOH consumption affects the kidney 
through pre- or post-translational regulation of protein abundance.  Furthermore, 
these modifications contribute to the kidneys response to a second acute 
nephrotoxic event, such as experimental endotoxemia (163, 164).  The current 
study addresses the hypothesis that chronic, moderate EtOH consumption 
significantly affects proteins, transcripts and canonical pathways in the kidney 
and the canonical response is modified by acute experimental endotoxemia (i.e. 
low dose LPS (10mg/kg) i.p.).   
First, we examined the effects of EtOH and LPS on renal function and tissue 
structure.  EtOH significantly increased BUN, a marker of kidney injury, as in a 
similar rodent model (87).  LPS increased BUN (24h > 4h) in the presence or 
absence of EtOH, consistent with other studies of the same dose of LPS in mice 
(165). The effects of chronic, moderate EtOH consumption on the kidney at the 
tissue level were largely indiscernible, as shown by PAS histology. Our data 
show no significant effect of EtOH recruitment of MPO-positive cells into the 




EtOH on LPS recruitment of MPO positive cells demonstrated a significant 
decrease at 4h post i.p. challenge that was lost at 24h. It is not clear if this 
difference was mitigated at the level of recruitment or clearance.  However, EtOH 
is known to enhance neutrophil apoptosis, which suggests that our observations 
may result from increased neutrophil clearance in the EtOH fed mice (165).   
Next, a discovery-based ‘omics (Fig. 2A) approach was used to unbiasedly 
identify proteins, transcripts, and canonical signaling pathways affected by 
chronic, moderate EtOH consumption.  EtOH significantly changed 92, 14, and 
109 proteins on a control, 4h LPS, and 24h LPS background, respectively.  It is 
known that TMT-based proteomic studies may underestimate fold-change 
differences (166), and therefore these numbers may underestimate the impact of 
chronic EtOH exposure on the renal proteome.  Specifically, a cluster of proteins 
that EtOH significantly decreased in abundance compared to control included 
Ehhadh, Acad11, Sqstm1, and Hnrnpc.  Ehhadh, Acad11 and Sqstm1 are 
important peroxisomal proteins involved in oxidation of fatty acids and regulation 
of peroxisomal matrix composition.  Many other proteins changed by EtOH are 
not known to play a role in EtOH-induced mechanisms in the kidney or other 
organs (Supplemental Data).  However, EtOH also increased the abundance of a 
cluster of ribosomal proteins (Rpl6, Rpl8, Rpl13a, and Rps15) on a background 
of 24h LPS.  Rpl13a (ribosomal protein L13a) has previously been described as 
a critical component of the interferon (IFN)-γ-activated inhibitor of translation or 
‘GAIT’ system (166).  The GAIT system is comprised of glutamyl-prolyl tRNA 




dehydrogenase. The increased abundance of a critical GAIT component in the 
EtOH + 24h LPS animals compared to the 24h LPS animals could contribute to 
an attenuated renal IFN-γ response in the two-hit model.  Further investigation 
would be needed to confirm up-regulation of the GAIT system as a protective 
measure for experimental endotoxemia in Lieber-DeCarli EtOH-fed animals. 
The transcriptomic study identified renal transcripts and pathways affected by 
EtOH and/or the early acute phase period following 4h LPS.  Hierarchical 
clustering of transcriptomic data demonstrates 6-7 major dendrogram arms of 
robust LPS-dependent transcriptomic changes (Fig. 5.4C).  For the renal 
transcriptome LPS had a 10-fold larger effect on regulated transcripts (q<0.05) 
and with larger fold-changes as compared to EtOH as the single hit (Table 1A).  
Quantitatively, chronic EtOH consumption consistently affected a sub-set of 
regulated transcripts (e.g. increased- KYNU, SLC7A12, decreased- CNTNAP5, 
CYP4A12A, GM6300, and KIF20B) even on a background of LPS exposure.  
The KYNU gene encodes the enzyme L-kynureninase that hydrolyzes 
kynurenine into anthranilate + L-alanine.  Tryptophan metabolites such as 
kynurenine have been reported to inhibit aldehyde dehydrogenase (Aldh) activity 
(167), and increased KYNU expression suggests an EtOH-dependent 
compensatory mechanism to increase the kidneys capacity to metabolize 
acetaldehyde, a toxic intermediate in the oxidation of EtOH. SLC7A12 is an Asc-
type cationic amino acid transporter (y+ system) and increased arginine uptake 
by endothelial Asc-type cationic amino acid transporters has been shown to blunt 




the murine genome.  Transcriptomic studies of 15-week old OVE26 kidneys 
identified 638 genes regulated by the diabetic state.  The single largest increased 
(SLC7A12) and decreased (GM6300) genes by informatics analyses were 
associated with endoplasmic reticulum (ER) stress (169).  EtOH-
independent/LPS-dependent mRNA expression (Table 5.1) changes modeled 
proteomic findings for acute phase stress response (Fga, Fgb, Fgg) or interferon-
responsive gene products (Ifit1, Ifit2, Saa2, and Lcn2).  Unlike previous studies in 
the liver and lung, LPS did not induce an EtOH-dependent synergistic increase 
the acute phase response gene products PAI-1 (1, 170). Our data for significant 
EtOH induction of renal CXCL1 (KC) (and CXCL10) transcript add to our prior 
report in plasma, liver and lung of the Lieber-DeCarli model requiring a two hit 
(EtOH + LPS) induction of KC (170).  The comparison of GO terms impacted by 
transcript regulation by EtOH suggested coordinated effects on a few transcripts 
associated with interferon response, innate immunity response and skeletal 
muscle development.  Consideration of GO features for transcripts regulated by 
EtOH pre-exposure on the LPS background clustered on terms for muscle cell 
proliferation and cell movement.  LPS as a single hit or second hit induced large 
changes in transcript numbers, affecting expected GO terms: innate immune 
response, cytokine response and positive regulation of cytokine production.  This 
more robust effect of 4h LPS on the transcriptome compared to EtOH is 
unsurprising, since LPS is well known to enhance and activate gene programs of 




of EtOH is muted as compared to the proteomic effect but in some regards 
parallels other murine disease models associated with ER stress. 
The proteomic and transcriptomic effects of EtOH and/or LPS were integrated 
using pathways analysis.  The integrated data revealed that EtOH, LPS, and 
EtOH + LPS have differential effects on unique protein canonical signaling 
pathways (Fig. 5.5A-B) related to transcription and translational signaling 
pathways, as well as stress response pathways, for example: inactivation of Nrf2 
(EtOH) and activation of the acute phase response or LXR/RXR (LPS) pathways.  
Activation of hepatic LXRα is associated fatty liver pathogensis (172). Activation 
of renal LXR has been shown to decrease cystic fibrosis transmembrane 
conductance regulator (CFTR)-mediated chloride transport (173) and 
downregulate sodium-phosphate cotransporters (173). The expected finding that 
LPS activated the acute phase response pathway increased our confidence in 
the unpredicted and novel findings, such as the overall inactivation of the Nrf2-
mediated oxidative stress response pathway (Fig. 5B).   
EtOH-induced downregulation of select proteins in the Nrf2-mediated 
oxidative stress response pathway was an unexpected finding, as EtOH is known 
to induce Nrf2 through Cyp2E1 in the liver (174).  Of the Nrf-2 targets, only Gclc 
was down-regulated by NextGen transcriptomic data (mRNA log2FC -1.38, q-
value<0.007).  In models of chronic kidney disease, Nrf2 pathway deactivation or 
knock-out is known to cause injury from increased oxidative stress and/or death 
(174-181).  However, the EtOH-downregulation of proteins in the Nrf2 pathway 




magnitude of BUN increase.  There are several possible explanations for this.  
First, EtOH activation of other transcription factors (e.g. Ahr, Sp1, or AP-1) 
successfully compensated for the downregulated components of the Nrf2 
pathway and protected against injury (182-184).  Second, the selective induction 
of Nqo1 or Sod2 may be based on the binding to the antioxidant response 
element (ARE) by unique Nrf2:cap n collar binding partner (e.g. Maf, MafF, MafB, 
MafG, or PMF-1) complexes with targeted transcriptional activity (185-187).  
Lastly, it is possible that neither the chronic, moderate EtOH consumption nor the 
acute endotoxemia in these mice caused sufficient oxidative stress for the 
decrease in select Nrf2 targets to be histologically deleterious.  
EtOH-dependent reduction of Nrf2-related proteins may occur through one or 
more of several potential mechanisms. Nrf2 is regulated by several mechanisms, 
typically divided in to those dependent or independent of Kelch-like ECH-
associated protein 1 (Keap1)(188).  One mechanism involves Nrf2 activation 
through the Sqstm1/p62-mediated deactivation of Keap1 (189).  In the present 
study, EtOH decreased Sqstm1/p62 abundance with or without LPS-exposure.  
EtOH exposure of neuronal cells in culture has been shown to lead to an 
activation of autophagic pathways that includes loss of Sqstm1/p62 (190).  
Therefore, EtOH may deactivate the Nrf2 stress response pathway by induction 
of autophagy, Sqstm1/p62 loss, and concomitant activation of Keap1.  These and 
other potential mechanisms of EtOH-induced dysregulation of the Nrf2-mediated 




Cat (a Nrf2 target) abundance in the Lieber-DeCarli model decreased by 40-
50% while the CAT mRNA was stable (Log2FC -0.08, q<0.999). This suggests a 
post-translational mechanism for decreased Cat abundance in the chronic 
setting. We hypothesized this decrease would be more pronounced in a more 
severe, acute-on-chronic NIAAA model (98) that better mimics human drinking 
patterns.  This would be an important finding as Cat plays a prominent role in 
hydrogen peroxide degradation and of the three known EtOH oxidizing enzymes 
(Ald, Cyp2E1, and Cat) is the most abundant in the renal cortex.  Our data 
demonstrated that in the NIAAA model, the chronic (10-day), acute (9h gavage), 
and acute-on chronic EtOH consumption all decreased Cat abundance in the 







DISCUSSION AND CONCLUSIONS 
 
A. Restatement of goals and questions 
The overall goal of the work described in this dissertation was to discover new 
potential mechanisms of alcohol-induced organ injury.  The work summarized in 
Chapter III aimed to test a novel method of analyzing the hepatic matrisome and 
use that approach to determine the effects of chronic, moderate ethanol 
consumption and acute inflammation on the hepatic matrisome in mice.  Chapter 
IV aimed to characterize the ECM degradome (peptidome) in AH patient plasma 
that will allow further investigation into the use of plasma ECM peptides as 
surrogate or mechanistic biomarkers.  Finally, Chapter V of this dissertation used 
a discovery based ‘omics approach to elucidate the effects of ethanol 
consumption on the kidneys.  Taken together, these studies provide new 
understanding of the complex mechanisms of alcohol-induced organ injury.   
 
B. Major findings of this dissertation 




The important role of the hepatic ECM in ALD pathophysiology is well known.  
However, research on this topic has been largely ‘collagenocentric’ and 
‘fibrosocentric’, that is, primarily focused on the role of the collagen matrix and 
the dramatic ECM changes in the fibrosis stage of disease.  It is now understood 
that the ECM is not simply a collagen scaffold, but a complex microenvironment 
that may be comprised of as many as 100 or more proteins at a time (191).  The 
group of proteins that makes up any specific ECM varies with organ and disease 
state, and is a dynamic subset of over 1000 known ECM-related proteins (92).  It 
is therefore unsurprising that recent studies have shown that multiple ECM 
proteins contribute to fibrosis (111).  However, it is also now known that the 
hepatic ECM is altered prior to fibrogenesis (89, 90).  A limitation of previous 
studies focused on the role of the ECM in ALD is that they generally studied 
changes in one ECM protein at a time and did not consider structural changes 
that may accompany altered ECM protein turnover.  Therefore the goal of 
Chapter III was to adapt a sequential protein extraction method originally 
developed for cardiac tissue (99, 114, 121) to allow proteomic analysis of global 
changes in the hepatic matrisome caused by chronic, moderate ethanol 
consumption and acute inflammation (LPS).  Furthermore, the sequential protein 
extraction method reveals potential changes in ECM protein crosslinking, 
location, and other aspects.  Overall, this approach provides new insight into 
novel matrisome protein changes caused by inflammatory stress.   
This approach divided the hepatic ECM proteome into four distinct extracts: 




membrane-associated proteins (SDS extract), (3) tightly bound ECM proteins 
(GnHCl extract), and (4) highly insoluble ECM components (the remaining pellet).  
Qualitative analysis of the matrisome demonstrated that both ethanol and LPS 
caused dynamic changes, with each exposure producing unique protein 
abundance patterns across the four fractions.  Indeed, ethanol and LPS each 
increased the number of matrisome proteins by ~25% compared to control.  The 
combination of ethanol and LPS demonstrated patterns similar to each individual 
exposure but also exhibited unique patterns.  The unique subsets of proteins 
qualitatively changed with ethanol and/or LPS may play critical roles in the 
hepatic response to stress.  Ethanol and/or LPS also quantitatively changed 
abundance of many proteins that did not change qualitatively.  These proteins 
are new potential key players in liver injury, whose roles can be determined in 
future studies.  Furthermore, analysis of ethanol-specific matrisome changes 
may provide new insights into the mechanisms of ethanol-sensitized liver injury, 
which could reveal novel therapeutic targets.  Most importantly, this work 
demonstrates the dynamic, global response of the hepatic matrisome to stress 
that opens a new, important area of future research.  This work also lays the 
foundation for future studies, such as the investigation of the ECM degradome in 
the plasma of AH patients described in Chapter IV. 
 
2. The plasma ECM degradome profile of alcoholic hepatitis patients 




Chapter IV of this dissertation aimed to characterize the plasma peptidome in 
AH patients.  This builds upon the work described in Chapter III of this 
dissertation, which demonstrated that the hepatic ECM undergoes significant 
remodeling during inflammatory liver injury in the absence of any apparent 
fibrosis (93).  This remodeling involves protease cleavage of ECM proteins, 
which yields ECM peptide fragments (94).  During remodeling, peptide fragments 
of the degraded ECM have been shown to increase in biologic fluids (e.g. 
plasma) (58, 59).  Peptidomic analysis of the degraded ECM (i.e., ‘degradome) 
has been identified as a useful diagnostic/prognostic tool in other diseases of 
ECM remodeling (such as metastatic cancers)(58, 59).  Current methods of 
predicting AH outcome (i.e. clinical scores, e.g. MELD) are limited in their abilities 
to predict at-risk patients with moderate disease(84).  We hypothesized that the 
severe inflammatory liver injury caused by AH would yield a unique degradome 
profile in patient plasma.   
In the pilot study described herein, a workflow was developed for the 
peptidomic analysis of plasma from healthy participants or AH patients.  AH 
severity was stratified by MELD score as mild (<12; n=45), moderate (12-19; 
n=23) or severe (>19; n=37).  Hierarchical clustering of the peptidomic data 
identified three strong groupings of peptide abundance patterns that reflected 
combinations of (A) increased peptide levels in healthy controls, (B) increased 
peptide levels in Moderate + Severe and (C) increased peptide levels in Mild-A + 
Mild-B AH cohorts.  Post-hoc filtering of the differentially abundant peptides 




differences noted in the collagen and fibrinogen peptides.  The unique patterns of 
ECM and other plasma peptides ‘features’ across different severity groups of AH 
patients can be confirmed using large longitudinal studies and can be 
investigated further as potential mechanistic or surrogate biomarkers for patient 
outcome.  The characterization of the AH plasma degradome also supports 
future mechanistic studies on the role of ECM remodeling in AH.   
 
3. Alcohol consumption alters renal cortical oxidant response 
pathways 
The studies in Chapter III and Chapter IV focus on the toxic effects of ethanol 
on its primary target organ, the liver.  In contrast to the liver, the effects of ethanol 
consumption on the kidneys are poorly understood.  Some human studies have 
reported benefits of chronic moderate EtOH consumption for preservation of 
renal function (85, 95).  However, the small number of rodent studies on the 
effects of ethanol on the kidneys have reported that chronic ethanol consumption 
upregulates CYP2E1 (88), causes neutrophil infiltration (88), and increases 
acetylation of mitochondrial proteins (86) in the kidney.  However, these previous 
studies have been limited by the hypothesis that ethanol affects the kidneys by 
mechanisms parallel to those in the liver.  To bypass this limitation, the study in 
Chapter V used an unbiased proteomic and transcriptomic approach to discover 
novel players and pathways affected by ethanol and LPS in the renal cortex.   
The proteomic analysis found that EtOH significantly changed 92, 14, and 




Interestingly, ethanol significantly decreased the abundance of a cluster of 
peroxisomal proteins compared to control.  Ethanol also increased the 
abundance of a cluster of ribosomal proteins on a background of 24-hour LPS.  
The effects of ethanol on the transcriptome were more muted than the effects on 
the proteome, suggesting that ethanol-induced protein may occur through 
degradation or other transcription-independent mechanisms.  Pathways analysis 
of integrated proteomic and transcriptomic data revealed that ethanol caused 
overall inactivation of the Nrf2-mediated oxidative stress response pathway.  This 
finding, which was confirmed with western blots, was surprising, as ethanol is 
known to induce Nrf2 in the liver (174).  This demonstrates the benefit of an 
unbiased, discovery-based approach.  Chronic ethanol consumption decreased 
Cat (a Nrf2 target) abundance by 40-50%.  The EtOH-associated effects on Cat 
were confirmed using a separate chronic-plus-binge (NIAAA) model.  This work 
uncovers novel potential mechanisms by which ethanol effects the kidneys that 
can be studied further in the future.  Most importantly, these findings reveal that 
chronic, moderate ethanol consumption affects the renal cortex at the protein and 
transcript level in the absence of tissue-level changes.   
 
C. Significance of new findings 
Chapter III describes a new method of analyzing the hepatic matrisome and 
revealed that the hepatic matrisome responds dynamically to stress.  The 
significance of this new method is that it can be adapted for analysis of the 




lung).  The finding that the hepatic matrisome responds dynamically to 
inflammatory stress is significant in that it provides a mechanistic link between 
steatohepatitis and fibrogenesis.  That ‘link’ is transitional ECM remodeling, 
which is thought to be a pivotal point between disease restitution and progression 
(1), and is therefore a promising target for new therapeutics.  The work in 
Chapter III identified specific protein players involved in remodeling that can be 
investigated as drug targets in future studies.  Furthermore, as ECM remodeling 
yields degradation products that can be secreted into bodily fluids, knowledge of 
remodeling also supports future investigations of the degradome (e.g. Chapter 
IV) and the eventual development of novel biomarkers.   
Plasma peptidomics is a novel approach for prognosis stratification in AH.  
The work in Chapter IV found that peptides in the plasma of AH patients change 
across groups separated by MELD score.  Interestingly, patients with lower 
MELD scores had dramatically higher abundances of plasma peptides than those 
with higher MELD scores.  This suggests that the degradome may be a positive 
predictor of outcome in AH.  Patient prognosis is a key factor in clinical risk-
benefit decision making regarding the administration of anti-inflammatory 
pharmacotherapeutics.  While this work could lead to novel surrogate 
biomarkers, understanding the peptidome can also provide insight into AH 
mechanisms.  For example, the peptidome in Chapter IV can be used to predict 
the proteases that generated it.  This protease activity can be validated and 
targeted in future studies, which could lead to new targeted therapies for AH.  




as mechanistic biomarkers for response to the targeted therapy.  Even apart from 
these possibilities, the fact that this work demonstrated that acute hepatic 
inflammation yields widespread, measurable changes in the plasma peptidome is 
significant in itself.   
The effects of ethanol consumption on the kidneys are poorly understood.  
The work in Chapter V demonstrated that although ethanol consumption does 
not cause histologically detectable changes in renal architecture, it does 
influence the renal cortex proteome and, to a lesser extent, transcriptome.  For 
example, ethanol consumption caused overall inactivation of the Nrf2 pathway, 
decreased abundance of peroxisomal proteins, and attenuated induction of LPS-
responsive genes.  This suggests unique effects of ethanol on the kidney that do 
not parallel those in the liver.  These data provide new hypotheses for future 
investigations on both the direct effects of ethanol on the kidneys and effects of 
ethanol on other renal pathologies.  More broadly, insight into the effects of 
ethanol on the kidneys contributes to understanding of alcohol toxicity, which 
could lead to new hypotheses and therapeutic approaches in the study of ALD.   
 
D. Strengths and weaknesses of this dissertation 
1. Strengths 
There are several strengths of this dissertation.  The first study provides 
insight into the role of transitional ECM changes in ethanol-sensitized hepatic 
inflammation (Chapter III) by characterizing the hepatic matrisome.  This work 




and subsequent LPS exposure.  Ethanol-sensitized hepatic inflammation is a 
complex phenomenon that is not confined to a single organ or cell type and 
cannot be wholly recapitulated in a simpler model (e.g. cell culture).  The use of 
an animal model as opposed to a human study allows many variables to be 
controlled, such as number of calories consumed, genetic variability, and 
environmental factors.  This increases confidence that ethanol and/or LPS are 
the variables that caused the experiment results.  Another strength is that a new 
method of protein extraction was validated for use with liver tissue, enabling the 
analysis of low-abundance and highly insoluble hepatic ECM proteins.  This 
allowed for a discovery-based proteomic characterization of the matrisome that 
provides a foundation for new hypothesis-driven studies and the identification of 
new therapeutic targets.  Importantly, this work also demonstrates that the 
hepatic matrisome responds dynamically to stress in the absence of fibrosis.   
The second study in this dissertation examines the plasma peptidome from 
AH patients with disease severity stratified by MELD score.  This investigation 
uses plasma from human patients, and so it does not rely on assumptions 
regarding the relevance of a model.  Another strength is that several different 
methods for the purification of peptides were tested, and the method which 
yielded the most pure peptidome was chosen.  Samples were handled randomly 
in flights that contained a number of samples from each group that was 
proportional to the total.  This minimizes any bias caused by sample handling.  
Samples were also spiked with a peptide standard prior to LC-MS/MS analysis to 




analysis of the peptidomic data accounted for several covariates, including 
participant age and sex.  The analysis included in this dissertation is preliminary, 
and future analyses will ensure that all appropriate covariates are considered.  
Another strength of this study is that patient plasma, as opposed to liver tissue, 
was analyzed.  This supports the future development of a minimally invasive 
diagnostic tool.   
The third study in this dissertation examines the effects of ethanol 
consumption on the renal cortex proteome and transcriptome.  This work 
employed the same mouse model of chronic, moderate ethanol consumption and 
a second ‘hit’ of LPS used in the first study in this dissertation.  Therefore, the 
same strengths associated with this model apply.  This model is well established 
and recapitulates the complexity of human alcohol consumption, while still 
controlling many variables.  Another strength of this work is that the proteomic 
workflow included TMT labeling, which allows reliable relative quantification of 
proteins between experimental groups.  This work also used a discovery-based 
‘omics approach, as opposed to a hypothesis driven approach.  Hypotheses by 
nature rely on previous knowledge, but very little is currently known about the 
effects of ethanol on the kidneys.  For this reason, a hypothesis-generating 
approach was chosen, which provides a foundation for future studies.  Indeed, 
several effects of ethanol on the kidneys were identified which would not have 
previously been expected.  It should also be noted that expected LPS-activation 




“positive control” that increases confidence in the less expected results of this 
study.   
 
2. Weaknesses 
The experiments described in Chapter III identified changes in the hepatic 
matrisome after alcohol and LPS exposure.  Although there are strengths 
associated with the use of a mouse model, there are also limitations that should 
be acknowledged.  Although in vivo experiments may recapitulate human 
disease more completely compared to in vitro experiments, in vivo research 
introduces more complexity and less control of variables.  Conversely, relevance 
to human disease may be questionable when mouse models are compared to 
human studies.  It is therefore possible that the observed matrisome changes are 
mouse-specific and have little direct relevance to humans.  While the inverse 
relationship between model relevance and ability to control variables can never 
be entirely avoided, it can be optimized for the question at hand and thoughtfully 
considered when interpreting results.  Another limitation of this study is that the 
biological replicate samples from the same fraction and same experimental group 
were pooled prior to LC-MS/MS analysis due to cost and time constraints.  This 
means that a sample from a single mouse could have driven the observed 
qualitative changes in protein abundance.  For this reason, follow-up studies are 
needed to confirm specific matrisome protein changes caused by ethanol and/or 
LPS.  Additionally, this study did not investigate the functional significance of 




The work in Chapter IV identified plasma peptides that change with disease 
severity in AH patients.  As with all human studies, there are many variables that 
cannot be controlled, and should therefore be included as covariates in statistical 
analyses.  The analyses included herein consider age and sex as covariates, but 
do not include other covariates, such as body mass index or race.  Plasma from 
different study groups was also collected at different sites, and so site-specific 
changes need to be statistically accounted for to the extent possible.  Therefore, 
it is possible that variables other than AH severity may be involved in the 
observed changes in peptide abundances.  As noted previously, the statistical 
analysis in this dissertation is a pilot study, and future analyses will more 
thoroughly address potential confounding variables.  Another limitation of this 
study is that it is cross-sectional, and so large scale longitudinal follow-up studies 
are needed to confirm the use of select peptides for outcome prediction.   
The work in Chapter V identifies proteins, transcripts and pathways affected 
by ethanol and/or LPS in the renal cortex.  The same mouse model was used in 
Chapter III.  Therefore, the same model-related limitations apply that were 
previously discussed.  As with any animal model, the relevance of the 
experimental results to human disease is not guaranteed, and neither is the 
assumption that all potential confounding variables have been controlled.  It 
should also be acknowledged that another study reported that a similar rat model 
of chronic ethanol consumption increased recruitment of MPO-positive cells into 
the kidney, whereas we did not observe this effect (87).  Another limitation is that 




known to cause signal suppression.  Therefore, the observed protein-level 
changes caused by ethanol and/or LPS may actually be greater than what was 
observed.  Additionally, it is standard practice to confirm phenomena of interest 
observed with an ‘omics approach using an additional method (e.g. immunoblot 
to confirm proteomics).  Some protein-level changes reported here were indeed 
confirmed with immunoblot, but other changes need to be confirmed in future 
studies.   
 
E. Future Directions 
While the experiments described in this dissertation answered specific gaps 
in our knowledge of alcohol-induced organ injury, it has also created new 
questions that will need to be addressed in future studies.  Three of these 
questions of these are discussed below. 
 
1. Does targeting the regulated “matrisome” proteins identified in 
Chapter III prevent, halt, or reverse alcohol-induced organ injury? 
The method described in Chapter III identified dynamic changes in the 
hepatic matrisome after ethanol and/or LPS exposure. However, whether any of 
these ECM proteins plays a critical role in alcohol-sensitized liver injury has yet to 
be determined.  To carry out this investigation, a select matrisome protein that 
was strongly and uniquely affected by ethanol in Chapter III could be genetically 
or pharmacologically targeted in a mouse model.  These mice could be 




inflammatory insult used in Chapter III.  Hepatic inflammatory injury in these mice 
could be examined with histology or other methods.  If targeting a protein 
mitigates damage, then that protein plays a critical role in damage.  For example, 
previous studies from our group demonstrated that the integrin inhibitor 
CycloRGDfV protects against liver injury and inflammation caused by acute 
ethanol exposure and LPS (192).  Such findings would support the targeting of 
the matrisome protein as a therapeutic strategy.   
 
2. Do the regulated peptides and features identified in Chapter IV 
predict alcoholic hepatitis patient outcome and/or response to 
treatment in longitudinal studies? 
The study in Chapter IV identifies plasma peptides of AH patients that change 
in abundance with disease severity.  Earlier in the discussion, it was noted that a 
limitation of this study is that it is cross-sectional and therefore does not follow 
the same patients over time.  Since this research asks the question whether 
peptide “features” can predict AH outcome, follow-up longitudinal outcome 
studies would help answer this question more definitively.  Such studies could 
also investigate the ability of regulated peptide “features” to predict response to 
treatment   
 
3. What are the mechanisms by which alcohol consumption alters the 





The experiments described in Chapter V identified the effects of ethanol 
consumption on renal cortex proteins and pathways using a discovery-based 
‘omics approach.  The mechanisms by which ethanol elicits these effects are 
unknown.  The transcriptomic analysis in Chapter V revealed that the effects of 
ethanol on the transcriptome were more muted than the effects on the proteome, 
suggesting that ethanol-induced protein changes may occur through altered 
protein degradation or other transcription-independent mechanisms.  Targeting 
one of these mechanisms in the same model of ethanol consumption used in 
Chapter V would help determine the contribution of that mechanism to the 
observed ethanol-induced effects.  Since the ethanol-induced effects have 
already been identified, they can now be detected with a more targeted method 
(e.g. immunoblot or PCR) instead of an ‘omics approach.  Additionally, molecular 
signaling programs (e.g. phosphorylation cascades) likely play a role in 
regulating the observed changes in protein abundance, and could be 
investigated with a proteomic approach (e.g. phosphoproteomics), or other 
methods.  It should be noted that others have used acetylomics to determine that 
chronic, moderate ethanol consumption causes mitochondrial hyperacetylation in 
rodent kidneys (86).  Links between this acetylomic data and the results in 
Chapter V could be investigated in future studies.   
 
F. Summary and Conclusions 
The overall goal of the work described in this dissertation was to elucidate 




proteomic approach for characterizing the hepatic matrisome.  That approach 
was used to characterize the dynamic response of the matrisome to the stress of 
chronic, moderate ethanol consumption and acute inflammation in mice.  This 
provides a foundation for future experiments to identify new players in transitional 
ECM remodeling.  Chapter IV demonstrated that AH causes detectable changes 
in the plasma ECM degradome/peptidome of patients.  These findings will allow 
future investigations into the use of plasma peptide ‘features’ as biomarkers for 
AH outcome.  Finally, Chapter V revealed the effects of chronic ethanol 
consumption and acute inflammation on the renal cortex proteome and 
transcriptome.  This work provides new hypotheses for future studies examining 
the effects of ethanol on the kidneys.  Taken together, this work reveals new 
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induced mechanisms in the liver, lung, and kidney. KBRIN Bioinformatics 
Group, University of Louisville, Louisville, KY. 
7. 6/2016. Platform Presentation. Characterization of the Impact of Ethanol 
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Changes in the Liver and Lung. Graduate Student Council Research 
Symposium, Louisville, KY. 
8. 10/2015. The Hepatic and Pulmonary “Matrisome” Responds Dynamically 
to Inflammatory Injury: Proteomic Characterization of the Transitional ECM 
Changes. Research!Louisville, Louisville, KY. 
9. 2015. The Hepatic “Matrisome” Responds Dynamically to Stress: Novel 
Characterization of the ECM Proteome. Atlantic Coast Conference Meeting 
of the Minds, Raleigh, NC. 
10. 2014. The Hepatic “Matrisome” Responds Dynamically to Stress: Novel 
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